var docs;if (!docs) docs =[]; docs["58"]={"5800":"<p><b>Title</b> QuiNINE / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of CarBAMazepine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Carefully consider the need for this combination due to the risk for impaired quinine effectiveness. Monitor patient response to both drugs closely. Specifically, monitor quinine effectiveness closely, watching for evidence of impaired effectiveness. Monitor for signs/symptoms of carbamazepine toxicity with use of this combination, including monitoring carbamazepine serum concentrations as appropriate.</p> \n<p><b>Discussion</b> According to quinine prescribing information, carbamazepine is expected to decrease quinine serum concentrations, potentially interfering with its clinical effectiveness.<sup>1</sup> Though quinine prescribing information recommends avoiding concurrent use with rifampin, another potent enzyme inducer, such a strong warning/recommendation is not included for carbamazepine. Quinine is a substrate for P-glycoprotein, CYP3A4, and other cytochrome P450 enzymes, and it is likely that carbamazepine-mediated induction of such transporters and enzymes is largely responsible for this suspected interaction.<sup>1</sup><br><br>The average carbamazepine AUC and maximum serum concentration (Cmax) were increased 104% and 56%, respectively, when single doses of carbamazepine (200 mg) and quinine sulfate (600 mg) were coadministered to a group of healthy volunteers (n=8).<sup>1,2</sup> The specific mechanism for this interaction is unclear, but quinine-mediated inhibition of CYP3A may be at least partially responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Qualaquin (quinidine). Philadelphia, PA: AR Scientific, Inc., 4/2011.</p>\n<p>2. Amabeoku GJ, Chikuni O, Akino C, et al, “Pharmacokinetic Interaction of Single Doses of Quinine and Carbamazepine, Phenobarbitone and Phenytoin in Healthy Volunteers,” <i>East Afr Med J</i>, 1993, 70(2):90-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8513749\">[PubMed 8513749]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5801":"<p><b>Title</b> QuiNINE / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> QuiNINE may increase the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of QuiNINE. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Carefully consider the need for this combination due to the risk for impaired quinine effectiveness. Monitor patient response to both drugs closely. Specifically, monitor quinine effectiveness closely, watching for evidence of impaired effectiveness. Monitor for signs/symptoms of phenobarbital toxicity with use of this combination, including monitoring phenobarbital serum concentrations as appropriate.</p> \n<p><b>Discussion</b> According to quinine prescribing information, phenobarbital is expected to decrease quinine serum concentrations, potentially interfering with its clinical effectiveness.<sup>1</sup> Though quinine prescribing information recommends avoiding concurrent use with rifampin, another potent enzyme inducer, such a strong warning/recommendation is not included for phenobarbital. Quinine is a substrate for P-glycoprotein, CYP3A4, and other cytochrome P450 enzymes, and it is likely that phenobarbital-mediated induction of such transporters and enzymes is largely responsible for this suspected interaction.<sup>1</sup><br><br>The average phenobarbital AUC and maximum serum concentration (Cmax) were increased 81% and 53%, respectively, when single doses of carbamazepine (120 mg) and quinine sulfate (600 mg) were coadministered to a group of healthy volunteers (n=8).<sup>1,2</sup> The specific mechanism for this interaction is unclear, but quinine-mediated inhibition of CYP3A, other drug metabolizing enzymes, and/or p-glycoprotein may be at least partially responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Qualaquin (quinidine). Philadelphia, PA: AR Scientific, Inc., 4/2011.</p>\n<p>2. Amabeoku GJ, Chikuni O, Akino C, et al, “Pharmacokinetic Interaction of Single Doses of Quinine and Carbamazepine, Phenobarbitone and Phenytoin in Healthy Volunteers,” <i>East Afr Med J</i>, 1993, 70(2):90-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8513749\">[PubMed 8513749]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5802":"<p><b>Title</b> QuiNINE / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of QuiNINE. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Carefully consider the need for this combination due to the risk for impaired quinine effectiveness. Monitor specifically for quinine effectiveness closely, watching for evidence of impaired effectiveness.</p> \n<p><b>Discussion</b> According to quinine prescribing information, phenytoin is expected to decrease quinine serum concentrations, potentially interfering with its clinical effectiveness.<sup>1</sup> Though quinine prescribing information recommends avoiding concurrent use with rifampin, another potent enzyme inducer, such a strong warning/recommendation is not included for phenytoin. Quinine is a substrate for P-glycoprotein, CYP3A4, and other cytochrome P450 enzymes, and it is likely that phenytoin-mediated induction of such transporters and enzymes is largely responsible for this suspected interaction.<sup>1</sup><br><br>The average phenytoin AUC and maximum serum concentration (Cmax) were increased by only 4% each, when single doses of phenytoin (200 mg) and quinine sulfate (600 mg) were coadministered to a group of healthy volunteers (n=8).<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Qualaquin (quinidine). Philadelphia, PA: AR Scientific, Inc., 4/2011.</p>\n<p>2. Amabeoku GJ, Chikuni O, Akino C, et al, “Pharmacokinetic Interaction of Single Doses of Quinine and Carbamazepine, Phenobarbitone and Phenytoin in Healthy Volunteers,” <i>East Afr Med J</i>, 1993, 70(2):90-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8513749\">[PubMed 8513749]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5803":"<p><b>Title</b> Vitamin K Antagonists / QuiNINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> QuiNINE may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased INR/prothrombin time (PT) or signs/symptoms of bleeding if quinine is initiated/dose increased, or decreased INR/PT if quinine is discontinued/dose decreased. Note that the INR/PT might be unchanged in the face of increased bleeding.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> Quinine prescribing information cautions that cinchona alkaloids, including quinine and quinidine, may increase the anticoagulant effect of vitamin K antagonists via inhibition of the hepatic synthesis of vitamin K-dependent coagulation proteins.<sup>1</sup> Due to the mechanism by which quinine may alter normal coagulation, this possible interaction may also extend to other anticoagulants.<br><br>Case reports describe bleeding episodes in warfarin-stable patients within a few days of initiating quinidine therapy.<sup>2,3,4</sup> In contrast, the prothrombin times of 10 warfarin-treated patients were unaffected by two weeks of concomitant quinidine therapy (800 mg/day).<sup>5</sup> The mechanism of these effects is unknown. The risk factors that might lead to effects in some patients, while not in others, is likewise unknown.<br><br>Studies in human liver microsomes and human hepatocyte suspensions both found that the 4'-hydroxylation of S-warfarin and the 10-hydroxylation of R-warfarin were increased 3- to 5-fold with concurrent quinidine.<sup>6</sup> Data from liver microsomes in different species of animals have similarly found an increase in R-warfarin 10-hydroxylation with quinidine, though there were considerable inter-species differences in the findings.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Qualaquin (quinidine). Philadelphia, PA: AR Scientific, Inc., 4/2011.</p>\n<p>2. Gazzaniga AB and Stewart DR, “Possible Quinidine-Induced Haemorrhage in a Patient on Warfarin Sodium,” <i>N Engl J Med</i>, 1969, 280:711. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5766081\">[PubMed 5766081]</a></p>\n<p>3. Koch-Weser J, “Quinidine-Induced Hypoprothrombinemic Haemorrhage in Patients on Chronic Warfarin Therapy,” <i>Ann Intern Med</i>, 1968, 68:511. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5643674\">[PubMed 5643674]</a></p>\n<p>4. Jones FL Jr, “More on Quinidine-Induced Hypoprothrombinaemia,” <i>Ann Intern Med</i>, 1986, 69:1074. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5698476\">[PubMed 5698476]</a></p>\n<p>5. Udall J, “Drug Interference With Warfarin Therapy,” <i>Clin Med</i>, 1970, 77:20.</p>\n<p>6. Ngui JS, Chen Q, Shou M, et al, “In Vitro Stimulation of Warfarin Metabolism by Quinidine: Increases in the Formation of 4'- and 10-Hydroxywarfarin,” <i>Drug Metab Dispos</i>, 2001, 29(6):877-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11353757\">[PubMed 11353757]</a></p>\n<p>7. Chen Q, Tan E, Strauss JR, et al, “Effect of Quinidine on the 10-Hydroxylation of R-Warfarin: Species Differences and Clearance Projection,” <i>J Pharmacol Exp Ther</i>, 2004, 311(1):307-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15163679\">[PubMed 15163679]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5804":"<p><b>Title</b> Monoamine Oxidase Inhibitors / OxyMORphone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> OxyMORphone may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Though not specifically contraindicated, oxymorphone prescribing information cautions that oxymorphone is not recommended to be used in patients who have received a monoamine oxidase (MAO) inhibitor within the past 14 days due to the potential for enhanced MAO inhibitor toxicity.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The prescribing information for oxymorphone notes that no specific interaction between oxymorphone and monoamine oxidase (MAO) inhibitors has been observed, but still cautions that oxymorphone is not recommended to be used in patients who have received a MAO inhibitor within the past 14 days due to the potential for enhanced MAO inhibitor toxicity.<sup>1</sup> Much of this concern appears related to observed interactions between other opiates and MAO inhibitors.<br><br>The specific mechanism for this potential interaction is unclear. The opiates meperidine and methadone appear to have specific effects on serotonin neurotransmission, effects that appear to be somewhat unique to these specific agents.<sup>2,3</sup> Other opiate derivatives, including buprenorphine, hydromorphone, and fentanyl have also been associated with reports of MAO inhibitor interactions;<sup>4,5,6</sup> however, there appears to be considerable variability among individual opiates with regards to their effects on serotonin neurotransmission.<sup>2,5,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Opana (oxymorphone). Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc., 03/2010.</p>\n<p>2. Gillman PK, “Monoamine Oxidase Inhibitors, Opioid Analgesics and Serotonin Toxicity,” <i>Br J Anaesth</i>, 2005, 95(4):434-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16051647\">[PubMed 16051647]</a></p>\n<p>3. Rogers KJ, “ Role of Brain Monoamines in the Interaction Between Pethidine and Tranylcypromine,” <i>Eur J Pharmacol</i>, 1971, 14(1)L86-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4252179\">[PubMed 4252179]</a></p>\n<p>4. Isenberg D, Wong SC, Curtis JA, “Serotonin Syndrome Triggered by a Single Dose of Suboxone,” <i>Am J Emerg Med</i>, 2008, 26(7):840.e3-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18774063\">[PubMed 18774063]</a></p>\n<p>5. Wittmann M, Schaaf T, Peters I, et al, “The Effects of Fentanyl-like Opioids and Hydromorphone on Human 5-HT<sub>3A</sub> Receptors,” <i>Anesth Analg</i>, 2008, 107(1):107-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18635474\">[PubMed 18635474]</a></p>\n<p>6. O'Hara JF Jr, Maurer WG, Smith MP, “Sufentanil-Isoflurane-Nitrous Oxide Anesthesia for a Patient Treated with Monoamine Oxidase Inhibitor and Tricyclic Antidepressant,” <i>J Clin Anesth</i>, 1995, 7(2):148-50. [PMID: 7598924]</p>\n<p>7. Codd EE, Shank RP, Schupsky JJ, et al, “Serotonin and Norepinephrine Uptake Inhibiting Activity of Centrally Acting Analgesics: Structural Determinants and Role in Antinociception,” <i>J Pharmacol Exp Ther</i>, 1995, 274:1263-70. [PMID: 7562497]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5805":"<p><b>Title</b> Propranolol / Ascorbic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ascorbic Acid may decrease the serum concentration of Propranolol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 5 healthy volunteers, administration of ascorbic acid (2 g single oral dose) 30 minutes prior to propranolol (80 mg single oral dose) decreased propranolol maximum concentration and AUC by 28% and 37%, respectively.<sup>1</sup> The mechanism and clinical significance of this interaction are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gonzalez JP, Valdivieso A, Calvo R, et al, “Influence of Vitamin C on the Absorption and First Pass Metabolism of Propranolol,” <i>Eur J Clin Pharmacol</i>, 1995, 48(3-4):295-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7589058\">[PubMed 7589058]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5806":"<p><b>Title</b> Ascorbic Acid / Aspirin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction has only been demonstrated with aspirin doses 600 mg or greater.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Aspirin may decrease the serum concentration of Ascorbic Acid. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Several observational and clinical studies, in both healthy volunteers and patients, have shown decreased ascorbate absorption and/or systemic concentrations during aspirin administration (from 600 mg single dose up to 3.9 g/day).<sup>1,2,3,4</sup> In contrast, one week of aspirin (3 g/day) had no effect on plasma ascorbate concentrations in healthy volunteers receiving varying dietary ascorbic acid content.<sup>5</sup><br><br>The mechanism and clinical importance of this interaction are unknown. Aspirin may decrease ascorbate absorption,<sup>1</sup> cause depletion of systemic ascorbate stores (e.g., in the gastric mucosa),<sup>2</sup> or both. Gastric ascorbate stores may be used in the process of neutralizing reactive oxygen species generated during aspirin treatment, which suggests a possible role in mediating the risk of aspirin induced gastric mucosal damage.<sup>6,7,8</sup> Ascorbic acid also may also decrease serum aspirin esterase activity,<sup>9</sup> but the clinical impact of this is likely low based on a study of choline salicylate.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Basu TK, “Vitamin C-Aspirin Interactions,” <i>Int J Vitam Nutr Res Suppl</i>, 1982, 23:83-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6811490\">[PubMed 6811490]</a></p>\n<p>2. Schulz HU, Schurer M, Krupp S, et al, “Effects of Acetylsalicylic Acid on Ascorbic Acid Concentrations in Plasma, Gastric Mucosa, Gastric Juice and Urine--A Double-Blind Study in Healthy Subjects,” <i>Int J Clin Pharmacol Ther</i>, 2004, 42(9):481-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15487806\">[PubMed 15487806]</a></p>\n<p>3. Sahud MA and Cohen RJ, “Effect of Aspirin Ingestion on Ascorbic-Acid Levels in Rheumatoid Arthritis,” <i>Lancet</i>, 1971, 1(7706):937-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4102269\">[PubMed 4102269]</a></p>\n<p>4. Loh HS, Watters K and Wilson CW, “The Effects of Aspirin on the Metabolic Availability of Ascorbic Acid in Human Beings,” <i>J Clin Pharmacol</i>, 1973, 13(11):480-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4490672\">[PubMed 4490672]</a></p>\n<p>5. Johansson U and Akesson B, “Interaction Between Ascorbic Acid and Acetylsalicylic Acid and Their Effects on Nutritional Status in Man,” <i>Int J Vitam Nutr Res</i>, 1985, 55(2):197-204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4040504\">[PubMed 4040504]</a></p>\n<p>6. Pohle T, Brzozowski T, Becker JC, et al, “Role of Reactive Oxygen Metabolites in Aspirin-Induced Gastric Damage in Humans: Gastroprotection by Vitamin C,” <i>Aliment Pharmacol Ther</i>, 2001, 15(5):677-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11328262\">[PubMed 11328262]</a></p>\n<p>7. Konturek PC, Kania J, Hahn EG, et al, “Ascorbic Acid Attenuates Aspirin-Induced Gastric Damage: Role of Inducible Nitric Oxide Synthase,” <i>J Physiol Pharmacol</i>, 2006, 57 Suppl 5:125-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17218764\">[PubMed 17218764]</a></p>\n<p>8. Dammann HG, Saleki M, Torz M, et al, “Effects of Buffered and Plain Acetylsalicylic Acid Formulations With and Without Ascorbic Acid on Gastric Mucosa in Healthy Subjects,” <i>Aliment Pharmacol Ther</i>, 2004, 19(3):367-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14984384\">[PubMed 14984384]</a></p>\n<p>9. Gupta JD, Gruca M and Ablett W, “Effect of Other Drugs and Chemicals on the Degradation of Aspirin in Vitro: Possible Extrapolation to In Vivo Metabolism of Aspirin,” <i>Eur J Drug Metab Pharmacokinet</i>, 1979, 4(2):103-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=488131\">[PubMed 488131]</a></p>\n<p>10. Hansten PD and Hayton WL, “Effect of Antacid and Ascorbic Acid on Serum Salicylate Concentration,” <i>J Clin Pharmacol</i>, 1980, 20(5-6 Pt 1):326-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7400368\">[PubMed 7400368]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5807":"<p><b>Title</b> Dofetilide / Triamterene</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Triamterene may increase the serum concentration of Dofetilide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination closely for signs/symptoms of dofetilide toxicity.</p> \n<p><b>Discussion</b> Dofetilide prescribing information warns that concurrent use of dofetilide with triamterene may result in increased dofetilide concentrations, and a resulting increase in the risk for toxicity, due to competition for renal tubular secretion.<sup>1</sup> Both dofetilide and triamterene undergo cationic secretion, creating a possibility for competitive inhibition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tikosyn (dofetilide). New York, NY: Pfizer Inc, November 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5808":"<p><b>Title</b> Dofetilide / AMILoride</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> AMILoride may increase the serum concentration of Dofetilide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination closely for signs/symptoms of dofetilide toxicity.</p> \n<p><b>Discussion</b> Dofetilide prescribing information warns that concurrent use of dofetilide with amiloride may result in increased dofetilide concentrations, and a resulting increase in the risk for toxicity, due to competition for renal tubular secretion.<sup>1</sup> Both dofetilide and amiloride undergo cationic secretion, creating a possibility for competitive inhibition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tikosyn (dofetilide). New York, NY: Pfizer Inc, November 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5809":"<p><b>Title</b> Dofetilide / MetFORMIN</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetFORMIN may increase the serum concentration of Dofetilide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination closely for signs/symptoms of dofetilide toxicity.</p> \n<p><b>Discussion</b> Dofetilide prescribing information warns that concurrent use of dofetilide with metformin may result in increased dofetilide concentrations, and a resulting increase in the risk for toxicity, due to competition for renal tubular secretion.<sup>1</sup> Both dofetilide and metformin undergo cationic secretion, creating a possibility for competitive inhibition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tikosyn (dofetilide). New York, NY: Pfizer Inc, November 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5810":"<p><b>Title</b> Amiodarone / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may enhance the QTc-prolonging effect of Amiodarone. Fosphenytoin may decrease the serum concentration of Amiodarone. Amiodarone may increase the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Seek alternatives to the concomitant use of amiodarone and fosphenytoin. If these agents are used in combination, monitor closely for evidence of QT interval prolongation or changes in cardiac rhythm, as well as for increased phenytoin serum concentrations/toxicity and reduced amiodarone concentrations/therapeutic effects.</p> \n<p><b>Discussion</b> Serum phenytoin concentrations have been reported to increase two to fourfold within a few weeks of initiating amiodarone therapy (400-1200 mg/day) with resultant phenytoin toxicity.<sup>1,2,3</sup> Pharmacokinetic studies in normal subjects showed that amiodarone (200 mg/day) for 3-6 weeks resulted in up to 40% increases in serum phenytoin concentrations.<sup>4,5</sup> Amiodarone likely inhibits the CYP2C9 metabolism of phenytoin.<br><br>In addition to the effects on phenytoin, serum amiodarone concentrations have been noted to decrease during concomitant therapy. Phenytoin administration (3-4 mg/kg/day) for 2 weeks caused serum amiodarone concentrations to decrease by 33% to 49% below predicted values.<sup>6,7</sup> This is likely due to phenytoin induction of CYP isoenzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. McGovern B, Geer VR, LaRaia PJ, et al, “Possible Interaction Between Amiodarone and Phenytoin,” <i>Ann Intern Med</i>, 1984, 101:650-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6486598\">[PubMed 6486598]</a></p>\n<p>2. Shackleford EJ and Watson FT, “Amiodarone-Phenytoin Interaction,” <i>Drug Intell Clin Pharm</i>, 1987, 21:921. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3678068\">[PubMed 3678068]</a></p>\n<p>3. Ahmad S, “Amiodarone and Phenytoin Interaction,” <i>J Am Geriatr Soc</i>, 1995, 43:1449-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7490410\">[PubMed 7490410]</a></p>\n<p>4. Nolan PE, Marcus FI, Hoyer GL, et al, “Pharmacokinetic Interaction Between Amiodarone and Phenytoin,” <i>J Am Coll Cardiol</i>, 1987, 9(2 Suppl A):47A.</p>\n<p>5. Nolan PE, Erstad BL, Hoyer GL, et al, “Steady-State Interaction Between Amiodarone and Phenytoin in Normal Subjects,” <i>Am J Cardiol</i>, 1990, 65:1252-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2337037\">[PubMed 2337037]</a></p>\n<p>6. Nolan PE, Marcus FI, Karol MD, et al, “Evidence for an Effect of Phenytoin on the Pharmacokinetics of Amiodarone,” <i>Pharmacotherapy</i>, 1998, 8:121.</p>\n<p>7. Nolan PE, Marcus FI, Karol MD, et al, “Effect of Phenytoin on the Clinical Pharmacokinetics of Amiodarone,” <i>J Clin Pharmacol</i>, 1990, 30:1112-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2273084\">[PubMed 2273084]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5812":"<p><b>Title</b> Vitamin K Antagonists / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued. Monitor anticoagulant status (i.e., INR) and for signs/symptoms of bleeding whenever this combination is used. Monitor for increased effects of warfarin, and significantly decreased effects of dicumarol, if phenytoin is initiated/dose increased, and the opposite effects if phenytoin is discontinued/dose decreased. Monitor for increased serum concentrations/toxic effects of phenytoin if a coumarin derivative is initiated/dose increased, or decreased serum concentrations/effects if a vitamin K antagonist is discontinued/dose decreased. These effects would most likely manifest during the first 1-2 months of therapy.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> PHENYTOIN IMPACT ON VITAMIN K ANTAGONISTS: One case report describes a 52% increase in prothrombin time (PT) in a warfarin-treated patient within a month of initiating phenytoin (300 mg/day) [this increase occurred in spite of a 22% decrease in warfarin dosage].<sup>1</sup> Another report describes the initial development of increased anticoagulant effects in a warfarin-treated patient and subsequent decreased anticoagulant effects (after approximately 6 days).<sup>2</sup> Several additional cases of increased/altered warfarin and acenocoumarol effects have been reported.<sup>3,4,5,6,7,8</sup> Significant decreases in the effects (commensurate with up to 75% decreases in serum concentrations) of dicumarol have been reported to occur within 1-2 months of initiating phenytoin therapy.<sup>9</sup> Several weeks can be required (post-phenytoin initiation) for dicumarol effects to normalize.<br><br>The exact mechanism(s) of these contrasting interactions is unclear. Phenytoin may cause an initial displacement of warfarin from protein binding sites, resulting in a transient increase in anticoagulant effects. These increased effects may then eventually be overcome by phenytoin induction of CYP isoenzymes involved in warfarin metabolism. As such, warfarin (aside from an initial monitoring period) would not likely cause significant clinical concern. Dicumarol, on the other hand, appears significantly affected by phenytoin. In addition, phenytoin may exert an independent effect on clotting factor concentrations and/or coagulation.<br><br>VITAMIN K ANTAGONIST IMPACT ON PHENYTOIN: Serum phenytoin concentrations (based on 300 mg/day) increased more than 2-fold in six healthy subjects within a week of initiating dicumarol.<sup>10</sup> A case report describes the development of phenytoin toxicity within a few days of initiating warfarin therapy.<sup>11</sup><br><br>The mechanism of this form of a phenytoin-vitamin K antagonist interaction is unclear. Dicumarol/warfarin may inhibit CYP2C9-mediated phenytoin metabolism.<br><br>Considering available data, it would appear as though warfarin would be a safer anticoagulant than dicumarol in phenytoin-treated patients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nappi JM, “Warfarin and Phenytoin Interaction,” <i>Ann Intern Med</i>, 1979, 90:852. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=434697\">[PubMed 434697]</a></p>\n<p>2. Levine M and Sheppard I, “Biphasic Interaction of Phenytoin and Warfarin,” <i>Clin Pharm</i>, 1984, 3:200-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6723231\">[PubMed 6723231]</a></p>\n<p>3. Koch-Weser J, “Haemorrhagic Reactions and Drug Interactions in 500 Warfarin Treated Patients,” <i>Clin Pharmacol Ther</i>, 1973, 14:139.</p>\n<p>4. Taylor JW, Alexander B, and Lyon LW, “A Comparative Evaluation of Oral Anticoagulant-Phenytoin Interactions,” <i>Drug Intell Clin Pharm</i>, 1980, 14:669-73.</p>\n<p>5. Abad-Santos F, Carcas AJ, F-Capitan C, et al, “Retroperitoneal Haematoma in a Patient Treated with Acenocoumarol, Phenytoin and Paroxetine,” <i>Clin Lab Haematol</i>, 1995, 17(2):195-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8536426\">[PubMed 8536426]</a></p>\n<p>6. Hassan Y, Awaisu A, Aziz NA, et al, “The Complexity of Achieving Anticoagulation Control in the Face of Warfarin-Phenytoin Interaction: An Asian Case Report,” <i>Pharm World Sci</i>, 2005, 27(1):16-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15861930\">[PubMed 15861930]</a></p>\n<p>7. Meisheri YV, “Simultaneous Phenytoin and Warfarin Toxicity on Chronic Concomitant Therapy,” <i>J Assoc Physicians India</i>, 1996, 44(9):661-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9251383\">[PubMed 9251383]</a></p>\n<p>8. Panegyres PK, Rischbieth RH, “Fatal Phenytoin Warfarin Interaction,” <i>Postgrad Med J</i>, 1991, 67(783):98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2057444\">[PubMed 2057444]</a></p>\n<p>9. Hansen JM, Siersbaek-Nielsen K, Kristensen M, et al, “Effect of Diphenylhydantoin on the Metabolism of Dicoumarol in Man,” <i>Acta Med Scand</i>, 1971, 189:15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4107730\">[PubMed 4107730]</a></p>\n<p>10. Hansen JM, Kristensen M, Skovsted L, et al, “Dicoumarol Induced Diphenylhydantoin Intoxication,” <i>Lancet</i>, 1966, ii:265. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4161425\">[PubMed 4161425]</a></p>\n<p>11. Rothermich NO, “Diphenylhydantoin Intoxication,” <i>Lancet</i>, 1966, ii:640.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5814":"<p><b>Title</b> Antifungal Agents (Azole Derivatives, Systemic) / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely. Consider selecting alternative antifungal therapy. Voriconazole and fluconazole may also substantially increase phenytoin exposure; ketoconazole and itraconazole may have less of an effect on phenytoin pharmacokinetics. If voriconazole and fosphenytoin must be used together, adjust voriconazole dose as follows: patients &gt; 40 kg should receive 400 mg oral twice daily, and patients &lt;40 kg should receive 200 mg oral twice daily. IV voriconazole maintenance doses should be 5 mg/kg every 12 hours. Also, serum phenytoin concentrations should be monitored, anticipating increased concentrations and the need to reduce the fosphenytoin dosage. If any azole antifungal is used concomitantly with phenytoin, monitor patients closely for azole therapeutic failure/relapse and phenytoin toxicity.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Itraconazole, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exception</b> Isavuconazonium Sulfate</p>\n</div> \n<p><b>Discussion</b> The AUC of itraconazole (single 200 mg dose) was reduced by &gt; 90% in 15 normal subjects when administered following a 15-day course of phenytoin (300 mg/day).<sup>1</sup> Six additional case reports describe therapeutic failure or relapse with itraconazole when concurrently receiving phenytoin alone or with phenobarbital.<sup>2,3</sup> Voriconazole (200mg twice daily) AUC was reduced by approximately 70% with multiple concurrent doses of phenytoin (300 mg daily) in a study of 21 healthy subjects.<sup>4</sup> Coccidioidal meningitis relapse has been reported with ketoconazole following phenytoin initiation.<sup>5</sup> In contrast, fluconazole (a triazole antifungal) concentrations do not appear to be affected by phenytoin.<sup>6</sup> A probable mechanism for these interactions is phenytoin induction of CYP3A4 resulting in increased metabolism of itraconazole, voriconazole, and ketoconazole.<br><br>Both voriconazole and fluconazole also appear to alter phenytoin pharmacokinetics. Voriconazole (400 mg twice daily) increased the average phenytoin AUC by approximately 80% in a study of 15 healthy volunteers.<sup>4</sup> Similarly, fluconazole (200mg daily) increased phenytoin AUC by an average of 75% more than placebo (n=20).<sup>6</sup> In another study, fluconazole (400 mg daily x 6 days) increased the phenytoin AUC by 33% following a single 250 mg phenytoin dose in 9 healthy volunteers.<sup>7</sup> Clinical phenytoin toxicity following initiation of higher doses of fluconazole have also been described.<sup>8</sup> Other azole antifungals appear to have less substantial effects on phenytoin pharmacokinetics. Single dose (300 mg) phenytoin AUC was an average of 10.3% higher after 15 days of itraconazole (200 mg daily) compared to baseline.<sup>1</sup> No other phenytoin pharmacokinetic parameters were significantly altered. Ketoconazole (200 mg twice daily x 6 days) also had no significant effects on phenytoin pharmacokinetics in a study of 9 healthy volunteers.<sup>7</sup> The suspected mechanism of this interaction is voriconazole and fluconazole inhibition of CYP2C9 and/or CYP2C19, both of which are important for phenytoin metabolism. Other azoles, such as itraconazole and ketoconazole, primarily inhibit CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ducharme MP, Slaughter RL, Warbasse LH, et al, “Itraconazole and Hydroxyitraconazole Serum Concentrations Are Reduced More Than Tenfold by Phenytoin,” <i>Clin Pharmacol Ther</i>, 1995, 58:617-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8529326\">[PubMed 8529326]</a></p>\n<p>2. Tucker RM, Denning DW, Hanson LG, et al, “Interaction of Azoles With Rifampin, Phenytoin, and Carbamazepine: <i>In vitro</i> and Clinical Observations,” <i>Clin Infect Dis</i>, 1992, 14:165-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1315160\">[PubMed 1315160]</a></p>\n<p>3. Hay RJ, Clayton YM, Moore MK, et al, “An Evaluation of Itraconazole in the Management of Onychomycosis,” <i>Br J Dermatol</i>, 1988, 119:359-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2846030\">[PubMed 2846030]</a></p>\n<p>4. Purkins L, Wood N, Ghahramani P, et al, “Coadministration of Voriconazole and Phenytoin: Pharmacokinetic Interaction, Safety, and Toleration,” <i>Br J Clin Pharmacol</i>, 2003, 56 Suppl 1:37-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616412\">[PubMed 14616412]</a></p>\n<p>5. Brass C, Galgiani JN, Blaschke TF, et al, “Disposition of Ketoconazole, an Oral Antifungal, in Humans,” <i>Antimicrob Agents Chemother</i>, 1982, 21:151-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6282204\">[PubMed 6282204]</a></p>\n<p>6. Blum RA, Wilton JH, Hilligoss DM, et al, “Effect of Fluconazole on the Disposition of Phenytoin,” <i>Clin Pharmacol Ther</i>, 1991, 49:420-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2015731\">[PubMed 2015731]</a></p>\n<p>7. Touchette MA, Chandrasekar PH, Milad MA, et al, “Contrasting Effects of Fluconazole and Ketoconazole on Phenytoin and Testosterone Disposition in Man,” <i>Br J Clin Pharmacol</i>, 1992, 34:75-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1633070\">[PubMed 1633070]</a></p>\n<p>8. Cadle RM, Zenon GJ, 3rd, Rodriguez-Barradas MC, et al, “Fluconazole-Induced Symptomatic Phenytoin Toxicity,” <i>Ann Pharmacother</i>, 1994, 28:191-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8173131\">[PubMed 8173131]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5815":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding the concomitant use of phenytoin and HMG-CoA reductase inhibitors. Monitor for decreased therapeutic effects of HMG-CoA reductase inhibitors if phenytoin is initiated/dose increased, or increased effects (possible toxicity) if phenytoin is discontinued/dose decreased. Red yeast rice contains lovastatin (possibly 2.4 mg per 600 mg of red yeast rice) and several other mevinic acid compounds.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pravastatin, Red Yeast Rice, Simvastatin<br><b>Exceptions</b> Pitavastatin, Rosuvastatin</p>\n</div> \n<p><b>Discussion</b> Case report. A simvastatin-stable patient (10 mg daily) experienced a 70% increase in total cholesterol following initiation of phenytoin (325 mg/day).<sup>1</sup> A fourfold simvastatin dosage increase resulted in better control, but still elevated cholesterol. Fluvastatin (40 mg/day) was unable to adequately control the patient's cholesterol. Better control was achieved on a reduced dosage of phenytoin (225 mg/day) plus atorvastatin (80 mg/day), and then later on atorvastatin without phenytoin. Phenytoin is a potent inducer of various CYP isoenzymes, and several HMG-CoA reductase inhibitors are substrates of these same isoenzymes. The result is increased metabolism of the antilipemic agents. Pravastatin is not significantly metabolized by CYP isoenzymes, but phenytoin may affect this agent via p-glycoprotein induction. Red yeast rice contains lovastatin (possibly 2.4 mg per 600 mg of red yeast rice) and several other mevinic acid compounds. Rosuvastatin does not appear to be affected by either CYP3A4 or p-glycoprotein.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Murphy MJ and Dominiczak MH, “Efficacy of Statin Therapy: Possible Effect of Phenytoin,” <i>Postgrad Med J</i>, 1999, 75:(884):359-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10435174\">[PubMed 10435174]</a></p>\n<p>2. Cooper KJ, Martin PD, Dane AL, et al, “Lack of Effect of Ketoconazole on the Pharmacokinetics of Rosuvastatin in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2003, 55(1):94-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12534645\">[PubMed 12534645]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5817":"<p><b>Title</b> Fosphenytoin / Benzodiazepines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of phenytoin if a benzodiazepine is initiated/dose increased, or decreased effects if a benzodiazepine is discontinued/dose decreased.</p>\n<div>\n <p><b>Benzodiazepines Interacting Members</b> Bromazepam, ChlordiazePOXIDE, CloBAZam, ClonazePAM, Clorazepate, DiazePAM, Estazolam, Ethyl Loflazepate, Etizolam, Flunitrazepam, Flurazepam, Loprazolam, LORazepam, Lormetazepam, Midazolam, Nitrazepam, Nordazepam, Oxazepam, Prazepam, Quazepam, Temazepam, Tofisopam, Triazolam<br><b>Exception</b> ALPRAZolam</p>\n</div> \n<p><b>Discussion</b> Data are inconsistent regarding any interactions that may exist between phenytoin and various benzodiazepines. A study in 25 phenytoin-stable patients (300-400 mg/day) showed a nearly twofold increase in serum phenytoin concentrations when patients also received either chlordiazepoxide or diazepam.<sup>1</sup> Several other reports described increased serum phenytoin concentrations when receiving concomitant benzodiazepines (including chlordiazepoxide, clonazepam, and diazepam).<sup>2,3,4,5</sup> In contrast, multipatient, multidose studies have demonstrated decreased serum phenytoin concentrations when such was administered with these same benzodiazepines.<sup>6,7,8,9</sup> Alprazolam has been reported to not interact with phenytoin.<sup>10</sup> The varied reported effects do not allow for clarity in understanding potential mechanisms of interaction. The ability for agents to inhibit and/or induce CYP isoenzymes is a potential explanation. Monitoring for potential changes in serum phenytoin concentrations, given the large changes reported in some studies, is warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vajda FJ E, Prineas RJ, and Lovell RRH, “Interaction Between Phenytoin and the Benzodiazepines,” <i>Lancet</i>, 1971, i:346.</p>\n<p>2. Shuttleworth E, Wise G, and Paulson G, “Choreoathetosis and Diphenylhydantoin Intoxication,” <i>JAMA</i>, 1974, 230:1170. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4479423\">[PubMed 4479423]</a></p>\n<p>3. Windorfer P, “Drug Interactions During Anticonvulsive Therapy,” <i>Int J Clin Pharmacol</i>, 1976, 14:236.</p>\n<p>4. Kutt H and McDowell FJ, “Management of Epilepsy With Diphenylhydantoin Sodium,” <i>JAMA</i>, 1968, 203:969. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5694319\">[PubMed 5694319]</a></p>\n<p>5. Murphy A and Wilbur K, “Phenytoin-Diazepam Interaction,” <i>Ann Pharmacother</i>, 2003, 37(5):659-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12708941\">[PubMed 12708941]</a></p>\n<p>6. Saavedra IN, Aguilera LI, Faure E, et al, “Case Report. Phenytoin/Clonazepam Interaction,” <i>Ther Drug Monit</i>, 1985, 7:481. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4082246\">[PubMed 4082246]</a></p>\n<p>7. Siris JH, Pippenger CE, Werner WL, et al, “Anticonvulsive Drug Serum Levels in Psychiatric Patients With Seizure Disorders,” <i>NY State J Med</i>, 1974, 74:1554.</p>\n<p>8. Houghton GW and Richens A, “The Effects of Benzodiazepines and Pheneturide on Phenytoin Metabolism in Man,” <i>Br J Clin Pharmacol</i>, 1974, 1:P344.</p>\n<p>9. Edwards VE and Eadie MJ, “Clonazepam - A Clinical Study of its Effectiveness as an Anticonvulsant,” <i>Proc Aus Assoc Neurol</i>, 1973, 10:61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4600355\">[PubMed 4600355]</a></p>\n<p>10. Patrias JM, DiPiro JT, Cheung RP, et al, “Effect of Alprazolam on Phenytoin Pharmacokinetics,” <i>Drug Intell Clin Pharm</i>, 1987, 21:2A.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5818":"<p><b>Title</b> Fosphenytoin / Calcium Channel Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Channel Blockers may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for phenytoin toxicity if a calcium channel blocker (CCB) is initiated/dose increased, or decreased phenytoin effects if a CCB is discontinued/dose decreased. Monitor for reduced CCB therapeutic effects with concomitant fosphenytoin. Nimodipine Canadian labeling contraindicates concomitant use with phenytoin.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, DilTIAZem*, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine*, Nilvadipine, NiMODipine*, Nisoldipine*, Nitrendipine, Verapamil*<br><b>Exception</b> Clevidipine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Signs of phenytoin toxicity developed in a patient within 2 weeks of initiating diltiazem therapy.<sup>1</sup> This effect was also reported in 2 of 14 patients in another study.<sup>2</sup> Another patient's serum phenytoin concentrations were approximately threefold higher while taking nifedipine.<sup>3</sup> It appears as though calcium channel blockers may affect phenytoin clearance, either by CYP3A4 isoenzyme inhibition (eg, diltiazem) or changes in hepatic blood flow (eg, nifedipine).<br><br>Phenytoin, as a CYP isoenzyme inducer (in particular, CYP3A4), also may affect the clearance of calcium channel blockers. The AUC of felodipine was approximately 94% lower in 10 patients also taking anticonvulsants (some of which were taking phenytoin alone) compared to 12 control patients.<sup>4</sup> The AUC (normalized) of nisoldipine (single 20 mg or 40 mg dose) was reduced nearly 90% in 12 patients also receiving phenytoin compared to 12 controls.<sup>5</sup> Another patient failed to achieve adequate serum verapamil concentrations until withdrawal of phenytoin therapy.<sup>6</sup> Nimodipine Canadian labeling describes an approximate 80% reduction in nimodipine bioavailability in epileptic patients receiving concurrent anticonvulsant therapy that included phenytoin.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Clarke WR, Horn JR, Kawabori I, et al, “Potentially Serious Drug Interaction Secondary to High-Dose Diltiazem Used in the Treatment of Pulmonary Hypertension,” <i>Pharmacotherapy</i>, 1993, 13:402-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8361869\">[PubMed 8361869]</a></p>\n<p>2. Bahls FH, Ozuna J, and Ritchie DE, “Interactions Between Calcium Channel Blockers and the Anticonvulsants Carbamazepine and Phenytoin,” <i>Neurology</i>, 41:740-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2027492\">[PubMed 2027492]</a></p>\n<p>3. Ahmad S, “Nifedipine-Phenytoin Interaction,” <i>J Am Coll Cardiol</i>, 1984, 3:1582. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6425385\">[PubMed 6425385]</a></p>\n<p>4. Capewell S, Freestone S, Critchley JA, et al, “Reduced Felodipine Bioavailability in Patients Taking Anticonvulsants,” <i>Lancet</i>, 1988, ii:480-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2900404\">[PubMed 2900404]</a></p>\n<p>5. Michelucci R, Cipolla G, Passarelli D, et al, “Reduced Plasma Nisoldipine Concentrations in Phenytoin-Treated Patients With Epilepsy,” <i>Epilepsia</i>, 1996, 37:1107-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8917062\">[PubMed 8917062]</a></p>\n<p>6. Woodcock BG, Kirsten R, Nelson K, et al, “A Reduction in Verapamil Concentrations With Phenytoin,” <i>N Engl J Med</i>, 1991, 325:1179. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1891033\">[PubMed 1891033]</a></p>\n<p>7. Product Monograph. Nimotop (nimodipine). Toronto, Ontario: Bayer Inc., April 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5819":"<p><b>Title</b> Fosphenytoin / Capecitabine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Capecitabine may increase the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Phenytoin dose reductions may be necessary when used together with capecitabine. Monitor phenytoin concentrations and response to therapy (both effectiveness and signs/symptoms of toxicity) closely when using this combination.</p> \n<p><b>Discussion</b> Capecitabine is a prodrug of floxuridine, which is partially converted further to fluorouracil in vivo.<sup>1</sup> Case reports have described phenytoin toxicity associated with concurrent use of capecitabine,<sup>2</sup> floxuridine,<sup>3</sup>, fluorouracil,<sup>2,4,5</sup> and tegafur (another fluorouracil prodrug).<sup>6,7</sup> A study in rats supports these reports, citing up to a 70-75% reduction in phenytoin metabolism in rats given fluorouracil or floxuridine.<sup>8</sup><br><br>The mechanism of this interaction appears to be capecitabine (i.e., fluorouracil/floxuridine)-mediated inhibition of phenytoin p-hydroxylation, a process normally dependent on CYP2C9. Though neither floxuridine or fluorouracil appear to have any direct inhibitory effect on CYP2C9 in microsomal studies,<sup>8,9</sup> studies in rats and patients with colorectal cancer have demonstrated decreased CYP2C9 activity (i.e., phenytoin hydroxylation<sup>8</sup> and losartan/E3174 ratio<sup>10</sup>) following treatment with both floxuridine<sup>8</sup> and fluorouracil<sup>8,10</sup> treatment. Of note, the inhibition appears time- and/or dose-dependent with greater inhibition after 3 cycles of fluorouracil (5.3-fold decrease) than after 1 cycle (28% decrease).<sup>10</sup> Studies with the CYP2C9 substrate warfarin further support this mechanism.<sup>11,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xeloda (capecitabine). Nutley, NJ: Roche Pharmaceuticals, April 2006.</p>\n<p>2. Brickell K, Porter D, Thompson P, “Phenytoin Toxicity Due to Fluoropyrimidines (5FU/Capecitabine): Three Case Reports,” <i>Br J Cancer</i>, 2003, 89(4):615-6.</p>\n<p>3. Konishi H, Morita K, Minouchi T, et al, “Probable Metabolic Interaction of Doxifluridine with Phenytoin,” <i>Ann Pharmacother</i>, 2002, 36(5):831-4.</p>\n<p>4. Gilbar PJ, Brodribb TR, “Phenytoin and Fluorouracil Interaction,” <i>Ann Pharmacother</i>, 2001, 35(11):1367-70.</p>\n<p>5. Rosemergy I, Findlay M, “Phenytoin Toxicity as a Result of 5-Fluorouracil Administration,” <i>N Z Med J</i>, 2002, 115(1159):U124.</p>\n<p>6. Tsuda A, Fujiyama J, Miki A, et al, “The First Case of Phenytoin Intoxication Associated with the Concomitant use of Phenytoin and TS-1, a Combination Preparation of Tegafur, Gimeracil, and Oteracil Potassium,” <i>Cancer Chemother Pharmacol</i>, 2008, 62(3):427-32.</p>\n<p>7. Wakisaka S, Shimauchi M, Kaji Y, et al, “Acute Phenytoin Intoxication Associated with the Antineoplastic Agent UFT,” <i>Fukuoka Igaku Zasshi</i>, 1990, 81(4):192-6.</p>\n<p>8. Konishi H, Yoshimoto T, Morita K, et al, “Depression of Phenytoin Metabolic Capacity by 5-Fluorouracil and Doxifluridine in Rats,” <i>J Pharm Pharmacol</i>, 2003, 55(1):143-9.</p>\n<p>9. Park JY, Kim KA, “Inhibitory Effect of 5-Fluorouracil on Human Cytochrome P(450) Isoforms in Human Liver Microsomes,” <i>Eur J Clin Pharmacol</i>, 2003, 59(5-6):407-9.</p>\n<p>10. Gunes A, Coskun U, Boruban C, et al, “Inhibitory Effect of 5-Fluorouracil on Cytochrome P450 2C9 Activity in Cancer Patients,” <i>Basic Clin Pharmacol Toxicol</i>, 2006, 98(2):197-200.</p>\n<p>11. Davis DA, Fugate SE, “Increasing Warfarin Dosage Reductions Associated with Concurrent Warfarin and Repeated Cycles of 5-Fluorouracil Therapy,” <i>Pharmacotherapy</i>, 2005, 25(3):442-7.</p>\n<p>12. Camidge R, Reigner B, Cassidy J, et al, “Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Cancer,” <i>J Clin Oncol</i>, 2005, 23(21):4719-25.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5820":"<p><b>Title</b> Fosphenytoin / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Fosphenytoin. CarBAMazepine may increase the serum concentration of Fosphenytoin. Possibly by competitive inhibition at sites of metabolism. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of carbamazepine or phenytoin if the other agent is initiated/dose increased, or increased serum concentrations/effects of one agent if the other is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Three of 7 patients in one study showed at least a 33% reduction in serum phenytoin concentrations within 4-14 days following the addition of carbamazepine (600 mg/day).<sup>1</sup> Similarly, carbamazepine serum concentrations are reported to be decreased in patients receiving phenytoin<sup>2,3,4</sup> In contrast, several reports of increased serum phenytoin concentrations (35% to 100%) have occurred in apparent response to carbamazepine therapy.<sup>5,6,7</sup> The mechanisms of these presumed interactions are seemingly related to the ability of the agents to affect, and be affected by, CYP isoenzymes. Both agents are known inducers of CYP isoenzymes, and likely stimulate the metabolism of the other agent (and possibly themselves). It's also possible, that acting as substrates for the same enzymes, they might compete against each other for metabolic sites, and thus reduce the metabolism of the other. The extent to which a particular mechanism manifests in a given patient is presently unpredictable, as therefore is the pharmacokinetic and clinical outcomes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hansen JM, Siersboek-Nielsen K, and Skovsted L, “Carbamazepine-Induced Acceleration of Diphenylhydantoin and Warfarin Administration in Man,” <i>Clin Pharmacol Ther</i>, 1971, 12(3):539-43.</p>\n<p>2. Cereghino JJ, Block JT, van Meter JC, et al, “The Efficacy of Carbamazepine Combinations in Epilepsy,” <i>Clin Pharmacol Ther</i>, 1975, 18(6):733-41.</p>\n<p>3. Ramsay RE, McManus DQ, Guterman A, et al, “Carbamazepine Metabolism in Humans: Effect of Concurrent Anticonvulsant Therapy,” <i>Ther Drug Monit</i>, 1990, 12(3):235-41.</p>\n<p>4. Chapron DJ, LaPierre BA, and Abou-Elkair M, “Unmasking the Significant Enzyme-Inducing Effects of Phenytoin on Serum Carbamazepine Concentrations During Phenytoin Withdrawal,” <i>Ann Pharmacother</i>, 1993, 27(6):708-11.</p>\n<p>5. Browne TR, Szabo GK, Evans JE, et al, “Carbamazepine Increases Phenytoin Serum Concentration and Reduces Phenytoin Clearance,” <i>Neurology</i>, 1988, 38(7):1146-50.</p>\n<p>6. Gratz ES, Theodore WH, Newmark ME, et al, “Effect of Carbamazepine on Phenytoin Clearance in Patients With Complex Partial Seizures,” <i>Neurology</i>, 1982, 32:A223.</p>\n<p>7. Zielinski JJ, Haidukewych D, and Leheta BJ, “Carbamazepine-Phenytoin Interaction: Elevation of Plasma Phenytoin Concentrations Due to Carbamazepine Comedication,” <i>Ther Drug Monit</i>, 1985, 7(1):51-3.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5821":"<p><b>Title</b> Fosphenytoin / CeFAZolin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CeFAZolin may decrease the protein binding of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for altered serum (free/unbound) concentrations/effects of phenytoin if cefazolin is initiated/dose increased.</p> \n<p><b>Discussion</b> In a retrospective review of phenytoin concentrations in critically ill children, 3 patients receiving cefazolin had significantly (85%) higher free phenytoin fraction than control patients.<sup>1</sup> The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wolf GK, McClain CD, Zurakowski D, et al, “Total Phenytoin Concentrations do not Accurately Predict Free Phenytoin Concentrations in Critically Ill Children,” <i>Pediatr Crit Care Med</i>, 2006, 7(5):434-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16885794\">[PubMed 16885794]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5823":"<p><b>Title</b> Ciprofloxacin (Systemic) / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may enhance the QTc-prolonging effect of Ciprofloxacin (Systemic). Ciprofloxacin (Systemic) may diminish the therapeutic effect of Fosphenytoin. Ciprofloxacin (Systemic) may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination closely for excessive QTc interval prolongation/arrhythmia, seizures, and decreased serum concentrations of phenytoin.</p> \n<p><b>Discussion</b> A case report describes a 61-year-old man stabilized on phenytoin 100 mg three times daily (level 12.6 mcg/mL).<sup>1</sup> Two days after initiation of ciprofloxacin (750 mg twice daily) he had a seizure and his serum phenytoin concentration was 2.5 mcg/mL. His phenytoin dose was titrated up to 200 mg three times daily and he once again achieved a serum concentration of 12.6 mcg/mL. Ciprofloxacin was discontinued while the higher phenytoin dose was continued and the patient experienced weakness, fatigue, ataxia, and a phenytoin level of 42.8 mcg/mL.<sup>1</sup> Several other case reports and letters describe similar decreases in phenytoin concentrations and subsequent seizures after initiation of ciprofloxacin.<sup>2,3,4,5</sup> One letter describes a patient taking ciprofloxacin, who upon initiation of phenytoin therapy, required escalating and higher than expected doses to achieve therapeutic concentrations.<sup>6</sup> Other reports describe patients stabilized on phenytoin who experienced seizures after initiation of ciprofloxacin without a change in phenytoin concentrations.<sup>5,7</sup><br><br>In contrast, a pharmacokinetic study conducted in 4 healthy volunteers found no change in phenytoin (200 mg daily on days 1 to 14) pharmacokinetics when combined with ciprofloxacin (500 mg twice daily given on days 10 to 14).<sup>8</sup> The authors do note that in one subject, the AUC and maximum serum concentration (Cmax) of phenytoin was reduced by 27% and 34%, respectively.<br><br>A single letter to the editor describes a possible increase in phenytoin concentrations due to ciprofloxacin, but the brevity of the report makes a causal relationship difficult to establish.<sup>9</sup><br><br>Ciprofloxacin product labeling recommends monitoring of phenytoin therapy, including phenytoin serum concentration measurements, during and shortly after concomitant use of ciprofloxacin and phenytoin.<sup>10</sup><br><br>The mechanism for the potential pharmacokinetic interaction (decreased phenytoin concentrations) is unknown, although alteration of gastrointestinal flora by ciprofloxacin and the resultant reduction in the enterohepatic circulation of phenytoin, has been proposed.<sup>3,4</sup> Additionally, animal data suggests that ciprofloxacin may increase the renal clearance of phenytoin.<sup>11</sup> The presence of a pharmacodynamic interaction (increase in seizure activity without serum level alterations) is likely due to the ability of ciprofloxacin to lower the seizure threshold, particularly in susceptible individuals (eg, those with a seizure disorder taking phenytoin).<sup>10</sup><br><br>In addition to the potential increase in seizure risk, both ciprofloxacin and fosphenytoin have been associated with QTc prolongation.<sup>10,12</sup> The concomitant use of moderate risk QTc-prolonging agents (eg, ciprofloxacin) with indeterminate risk/risk modifying QTc-prolonging agents (eg, fosphenytoin) should be performed with caution; close monitoring for evidence of excessive QT prolongation and/or torsades de pointes (TdP) may be advisable. Such concomitant use may substantially increase the risk for serious toxicities, including the development of TdP or other significant ventricular tachyarrhythmias. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, higher drug concentrations), would be at an even higher risk for these potentially life-threatening toxicities.<sup>13,14,15,16</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pollak PT, Slayter KL. Hazards of doubling phenytoin dose in the face of an unrecognized interaction with ciprofloxacin. <i>Ann Pharmacother</i>. 1997;31(1):61-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8997469\">[PubMed 8997469]</a></p>\n<p>2. Dillard ML, Fink RM, Parkerson R. Ciprofloxacin-phenytoin interaction. <i>Ann Pharmacother</i>. 1992;26(2):263. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1554944\">[PubMed 1554944]</a></p>\n<p>3. Brouwers PJ, de Boer LE, Guchelaar HJ. Ciprofloxacin-phenytoin interaction. <i>Ann Pharmacother</i>. 1997;31(4):498. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9101016\">[PubMed 9101016]</a></p>\n<p>4. Otero MJ, Moran D, Valverde MP. Interaction between phenytoin and ciprofloxacin. <i>Ann Pharmacother</i>. 1999;33(2):251-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10084426\">[PubMed 10084426]</a></p>\n<p>5. Springuel P. Risk of seizures from concomitant use of ciprofloxacin and phenytoin in patients with epilepsy. <i>CMAJ</i>. 1998;158(1):108-109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9475922\">[PubMed 9475922]</a></p>\n<p>6. McLeod R, Trinkle R. Comment: unexpectedly low phenytoin concentration in a patient receiving ciprofloxacin. <i>Ann Pharmacother</i>. 1998;32(10):1110-1111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9793610\">[PubMed 9793610]</a></p>\n<p>7. Slavich IL, Gleffe RF, Haas EJ. Grand mal epileptic seizures during ciprofloxacin therapy. <i>JAMA</i>. 1989;261(4):558-559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2491893\">[PubMed 2491893]</a></p>\n<p>8. Job ML, Am SK, Strom JG, Jacobs NF, D’Souza MJ. Effect of ciprofloxacin on the pharmacokinetics of multiple-dose phenytoin serum concentrations. <i>Ther Drug Monit</i>. 1994;16(4):427-431. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7974636\">[PubMed 7974636]</a></p>\n<p>9. Hull RL. Possible phenytoin-ciprofloxacin interaction. <i>Ann Pharmacother</i>. 1993;27(10):1283. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8251700\">[PubMed 8251700]</a></p>\n<p>10. <i>Cipro</i> (ciprofloxacin) [prescribing information]. Wayne, NJ: Bayer Health Pharmaceuticals Inc; July 2013.</p>\n<p>11. al-Humayyd MS. Ciprofloxacin decreases plasma phenytoin concentrations in the rat. <i>Eur J Drug Metab Pharmacokinet</i>. 1997;22(1):35-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9179558\">[PubMed 9179558]</a></p>\n<p>12. <i>Cerebyx</i> (fosphenytoin) [prescribing information]. New York, NY: Pfizer Inc; April 2014.</p>\n<p>13. Drew BJ, Ackerman MJ, Funk M, et al; American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology; Council on Cardiovascular Nursing; American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. <i>J Am Coll Cardiol</i>. 2010;55(9):934-947. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20185054\">[PubMed 20185054]</a></p>\n<p>14. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Guidance for Industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073153.pdf. Published October 2005. Accessed July 16, 2014.</p>\n<p>15. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. <i>Pharmacol Rev</i>. 2010;62(4):760-781. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21079043\">[PubMed 21079043]</a></p>\n<p>16. Ponte ML, Keller GA, Di Girolamo G. Mechanisms of drug induced QT interval prolongation. <i>Curr Drug Saf</i>. 2010;5(1):44-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20210718\">[PubMed 20210718]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5827":"<p><b>Title</b> CycloSPORINE (Systemic) / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of cyclosporine if phenytoin is initiated/dose increased, or increased serum concentrations/effects if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC and maximum serum concentration of cyclosporine (15 mg/kg single dose) were decreased by 47% and 37%, respectively, in 6 normal subjects while receiving phenytoin (300-400 mg/day).<sup>1</sup> Reductions in serum cyclosporine concentrations in conjunction with phenytoin administration have been elsewhere reported.<sup>2,3,4,5,6</sup> Phenytoin is a known inducer of CYP isoenzymes, including CYP3A4 for which cyclosporine is a substrate. Such induction would increase the metabolism of the cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Freeman DJ, Laupacis A, Keown PA, et al, “Evaluation of Cyclosporine-Phenytoin Interaction With Observations on Cyclosporine Metabolites,” <i>Br J Clin Pharmacol</i>, 1984, 18:887-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6529529\">[PubMed 6529529]</a></p>\n<p>2. Keown PA, Laupacis A, Carruthers G, et al, “Interaction Between Phenytoin and Cyclosporine Following Organ Transplantation,” <i>Transplantation</i>, 1984, 38:304-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6474556\">[PubMed 6474556]</a></p>\n<p>3. Keown PA, Stiller CR, Laupacis AL, et al, “The Effects and Side Effects of Cyclosporine: Relationship to Drug Pharmacokinetics,” <i>Transplant Proc</i>, 1982, 14:659-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6762722\">[PubMed 6762722]</a></p>\n<p>4. Grigg-Damberger MM, Costanzo-Nordin R, Kelly MA, et al, “Phenytoin May Compromise Efficacy of Cyclosporine Immunosuppression in Cardiac Transplant Patients,” <i>Epilepsia</i>, 1988, 29:693.</p>\n<p>5. Schmidt H, Naumann R, Jaschonek K, et al, “Drug Interaction Between Cyclosporine and Phenytoin in Allogeneic Bone Marrow Transplantation,” <i>Bone Marrow Transplant</i>, 1989, 4:212-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2650795\">[PubMed 2650795]</a></p>\n<p>6. Formea CM, Evans CG, and Karlix JL, “Altered Cytochrome P450 Metabolism of Calcineurin Inhibitors: Case Report and Review of the Literature,” <i>Pharmacotherapy</i>, 2005, 25(7):1021-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16006281\">[PubMed 16006281]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5828":"<p><b>Title</b> Darunavir / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Darunavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of darunavir with phenytoin.</p> \n<p><b>Discussion</b> The manufacturer of darunavir states that concomitant use with phenytoin should be avoided. <sup>1</sup> Decreased plasma concentrations possibly resulting in a decreased therapeutic effect of the protease inhibitor may be observed. This interaction is likely the result of a phenytoin mediated induction of CYP metabolism of darunavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Prezista (darunavir). Raritan, NJ: Tibotec Therapeutics, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5829":"<p><b>Title</b> Deferasirox / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Deferasirox. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.</p> \n<p><b>Discussion</b> In a study described in deferasirox prescribing information, mean deferasirox AUC was reduced by 44% following administration of a single dose of deferasirox (30mg/kg) to subjects receiving rifampin (600mg/d x 9 days).<sup>1</sup> The suspected mechanism of this interaction is rifampin-mediated induction of deferasirox metabolism via induction of UGT1A1, which is primarily responsible for the metabolism (via glucuronidation) of deferasirox.<sup>1</sup> The prescribing information recommends avoiding concurrent use when possible, but if this combination is used, consider a 50% increase in initial dose of deferasirox, with monitoring of serum ferritin concentrations/clinical responses to guide further dose adjustment.<sup>1</sup> Like rifampin, phenytoin is a potent inducer of several metabolic enzymes and is specifically mentioned in deferasirox prescribing information.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Exjade (deferasirox). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 09/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5830":"<p><b>Title</b> Fosphenytoin / Dexmethylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexmethylphenidate may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxicity of phenytoin if dexmethylphenidate is initiated/dose increased. Dosage adjustments may be required.</p> \n<p><b>Discussion</b> Prescribing information for dexmethylphenidate states that human pharmacologic studies have been conducted showing that methylphenidate may inhibit the metabolism of anticonvulsants including phenytoin.<sup>1</sup> Case reports of phenytoin intoxication following methylphenidate initiation have been reported.<sup>2,3</sup> However, a number of other case reports have been published where this effect was not detected.<sup>4,5</sup><br><br>The mechanism of this potential interaction is unclear, as are the frequency of occurrence and potential clinical significance. Methylphenidate isomer studies have not been conducted to elucidate the relative contributions of the d-threo (dexmethylphenidate) and l-threo enantiomers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Focalin (dexmethylphenidate hydrochloride). East Hanover, New Jersey: Novartis Pharmaceuticals Corporation, April 2007.</p>\n<p>2. Garrettson KJ, Perel JM, and Dayton PG, “Methylphenidate Interaction With Both Anticonvulsants and Ethyl Biscoumacetate,” <i>JAMA</i>, 1969, 207:2053-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5818377\">[PubMed 5818377]</a></p>\n<p>3. Ghofrani M, “Possible Phenytoin-Methylphenidate Interaction,” <i>Dev Med Child Neurol</i>, 1988, 30(2):267-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3133263\">[PubMed 3133263]</a></p>\n<p>4. Mirkin BL and Wright F, “ Drug Interactions: Effects of Methylphenidate on the Disposition of Diphenylhydantoin in Man,” <i>Neurology</i>, 1971, 21:1123-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5166217\">[PubMed 5166217]</a></p>\n<p>5. Kupferberg HJ, Jeffery W, and Hunninghake DB, “Effect of Methylphenidate on Plasma Anticonvulsant Levels,” <i>Clin Pharmacol Ther</i>, 1972, 13:201-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4552820\">[PubMed 4552820]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5831":"<p><b>Title</b> Fosphenytoin / Diazoxide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Diazoxide may decrease the serum concentration of Fosphenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of phenytoin if diazoxide is initiated/dose increased, or increased effects if diazoxide is discontinued/dose decreased. Free phenytoin concentrations may be a preferred means of monitoring therapy as protein binding displacement may be involved in this interaction, and total phenytoin concentrations may not be an adequate reflection of how much “active” (i.e., free or unbound) phenytoin is present.</p> \n<p><b>Discussion</b> Serum phenytoin concentrations were significantly decreased in 3 pediatric patients during concomitant therapy with diazoxide.<sup>1,2,3</sup> Serum concentrations increased (and needed phenytoin dosages decreased) upon discontinuation of diazoxide. Upon rechallenge, one patient's serum phenytoin concentration decreased to undetectable levels and the patient experienced seizures.<sup>1,2</sup> The mechanism of this interaction is uncertain, but there was evidence that diazoxide decreased phenytoin protein binding.<sup>2</sup> This decreased protein binding together with evidence of increased urinary excretion of the major phenytoin metabolite<sup>2</sup> suggests that protein binding displacement by diazoxide led to greater clearance (because greater proportion of unbound phenytoin available for metabolism) and a decrease in total phenytoin concentrations. Assessment of free phenytoin concentrations would likely be a preferable means of monitoring therapy in patients using this combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Roe TF, Podosin RL, and Blaskovics MR, “Drug Interaction. Diazoxide and Diphenylhydantoin,” <i>Pediatr Res</i>, 1975, 9:285.</p>\n<p>2. Roe TF, Podosin RL, and Blaskovics ME, “Drug Interaction. Diazoxide and Diphenylhydantoin,” <i>J Pediatr</i>, 1975, 87:480. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1165331\">[PubMed 1165331]</a></p>\n<p>3. Petro DJ, Vannucci RC, and Kulin HE, “Diazoxide-Diphenylhydantoin Interaction,” <i>J Pediatr</i>, 1976, 89:331. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=940040\">[PubMed 940040]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5832":"<p><b>Title</b> Fosphenytoin / Disopyramide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Disopyramide may enhance the QTc-prolonging effect of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Disopyramide. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Seek alternatives to the concomitant use of disopyramide and fosphenytoin. If these agents are used in combination, monitor closely for evidence of QT interval prolongation or changes in cardiac rhythm, as well as for decreased serum concentrations and therapeutic effects of disopyramide.</p> \n<p><b>Discussion</b> Several reports describe decreases in serum disopyramide concentrations ranging from 30% to 75% in patients following the initiation of phenytoin therapy.<sup>1,2,3,4</sup> These pharmacokinetic changes occurred within approximately 1 week of initiation of combination therapy. Evidence of reduced disopyramide efficacy was noted in some cases (e.g., increased frequency of PVCs). The mechanism of this interaction is uncertain but is likely related to the ability of phenytoin to induce CYP3A4 enzymes of which disopyramide is a substrate.<br><br>In addition to the above pharmacokinetic interaction between these agents, coadministration of fosphenytoin may increase the risk for QT interval prolongation and/or torsades de pointes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aitio ML and Vuorenmaa T, “Enhanced Metabolism and Diminished Efficacy of Disopyramide by Enzyme Induction,” <i>Br J Clin Pharmacol</i>, 1980, 9:149-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7356902\">[PubMed 7356902]</a></p>\n<p>2. Aitio ML, Mansury L, Tala E, et al, “The Effect of Enzyme Induction on the Metabolism of Disopyramide in Man,” <i>Br J Clin Pharmacol</i>, 1981, 279-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7213529\">[PubMed 7213529]</a></p>\n<p>3. Kessler JM, Keys PW, and Stafford RW, “Disopyramide and Phenytoin Interaction,” <i>Clin Pharm</i>, 1982, 1:263-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7185523\">[PubMed 7185523]</a></p>\n<p>4. Nightingale J and Nappi JM, “Effect of Phenytoin on Serum Disopyramide Concentrations,” <i>Clin Pharm</i>, 1987, 6:46-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3816106\">[PubMed 3816106]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5833":"<p><b>Title</b> Fosphenytoin / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Disulfiram may increase the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> If possible, avoid concomitant use of disulfiram and phenytoin. Monitor for increased serum concentrations/toxic effects of phenytoin if disulfiram is initiated or the dose is increased. Reduced phenytoin dosage will likely be needed. Monitor for decreased serum concentrations/effects of phenytoin if disulfiram is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Case reports demonstrate increases in serum phenytoin concentrations of at least 500% occurring over the course of several days following the initiation of disulfiram, with signs of toxicity occurring in some.<sup>1,2</sup> Notable changes started to occur within a few hours of initiating disulfiram, and lasted for several days (up to 3 weeks) following discontinuation of the disulfiram. Other similar reports are available.<sup>3,4,5</sup> An additonal case report describes a seizure episode occurring shortly after discontinuation of disulfiram in a patient who had previously been taking both phenytoin and disulfiram.<sup>6</sup><br><br>The mechanism of this interaction is unclear. Several studies have reported evidence of decreased phenytoin metabolism/clearance and increased elimination half-life with concurrent disulfiram.<sup>2,3,4</sup> Considering the primary role of CYP2C9 in phenytoin metabolism, disulfiram-mediated inhibition of CYP2C9 has been suggested as a possible mechanism. However, concurrent use of disulfiram with the model CYP2C9 substrate tolbutamide was not associated with any significant changes in tolbutamide half-life or clearance in a study of healthy volunteers,<sup>3</sup> and another study also concluded that single-dose disulfiram had no significant effect on CYP2C9 activity (measured as tolbutamide metabolic ratio) in vivo.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Olesen OV, “Disulfiram (Antabuse) as Inhibitor of Phenytoin Metabolism,” <i>Acta Pharmacol et Toxicol</i>, 1966, 24:317. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6013115\">[PubMed 6013115]</a></p>\n<p>2. Olesen OV, “The Influence of Disulfiram and Calcium Carbamide on the Serum Diphenylhydantoin Excretion of HPPH in the Urine,” <i>Arch Neurol</i>, 1967, 16:642. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6026073\">[PubMed 6026073]</a></p>\n<p>3. Svendesen TL, Kristensen MB, Hansen JM, et al, “The Influence of Disulfiram on the Half-Life and Metabolic Clearance Rate of Diphenylhydantoin and Tolbutamide in Man,” <i>Eur J Clin Pharmacol</i>, 1976, 9:439.</p>\n<p>4. Taylor JW, Alexander B, and Lyon LW, “Mathematical Analysis of a Phenytoin-Disulfiram Interaction,” <i>Am J Hosp Pharm</i>, 1981, 38:93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7211876\">[PubMed 7211876]</a></p>\n<p>5. Brown CG, Kaminsky MJ, Feroli ER Jr, et al, “Delirium with Phenytoin and Disulfiram Administration,” <i>Ann Emerg Med</i>, 1983, 12(5):310-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6625283\">[PubMed 6625283]</a></p>\n<p>6. Birkett DJ, Graham GG, Chinwah PM, et al, “Multiple Drug Interactions with Phenytoin,” <i>Med J Aust</i>, 1977, 2(14):467-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=600148\">[PubMed 600148]</a></p>\n<p>7. Kharasch ED, Hankins DC, Jubert C, et al, “Lack of Single-Dose Disulfiram Effects on Cytochrome P-450 2C9, 2C19, 2D6, and 3A4 Activities: Evidence for Specificity Toward P-450 2E1,” <i>Drug Metab Dispos</i>, 1999, 27(6):717-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10348802\">[PubMed 10348802]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5834":"<p><b>Title</b> Loop Diuretics / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may diminish the diuretic effect of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of loop diuretics if phenytoin is initiated/dose increased, or increased effects if phenytoin is discontinued/dose decreased.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> The absorption of furosemide (20 mg orally) was reduced by approximately 50% in a study of 5 healthy volunteers when administered following a 10-day course of phenytoin (300 mg/day).<sup>1</sup> The associated diuretic response to furosemide was also reduced with phenytoin. Another study (N=17) reported similar findings of diminished (and delayed) diuretic response to furosemide with concurrent anticonvulsant therapy (all subjects were receiving phenytoin and phenobarbital, some were also receiving other anticonvulsants).<sup>2</sup> The mechanism of this interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fine A, Henderson JS, Morgan DR, et al, “Malabsorption of Frusemide Caused by Phenytoin,” <i>Br Med J</i>, 1977, 2:1061-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=922420\">[PubMed 922420]</a></p>\n<p>2. Ahmad S, “Renal Insensitivity to Frusemide Caused by Chronic Anticonvulsant Therapy,” <i>Br Med J</i>, 1974, 3:657-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4609534\">[PubMed 4609534]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5836":"<p><b>Title</b> Fosphenytoin / DOPamine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> DOPamine may enhance the hypotensive effect of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased blood pressure in patients receiving intravenous phenytoin. Hemodynamically unstable patients, including those requiring dopamine to maintain adequate blood pressure, are at elevated risk.</p> \n<p><b>Discussion</b> Five case reports document significant and rapid reductions in blood pressure (previously maintained via a dopamine infusion) following the initiation of phenytoin infusion for seizure control.<sup>1</sup> One patient died from cardiopulmonary arrest. Another patient (receiving dopamine and dobutamine) did not experience any blood pressure change when a phenytoin infusion was initiated.<sup>2</sup> <br><br>The mechanism of this possible interaction is unknown. Hypotension is a known possible adverse effect of intravenous phenytoin administration, particularly in hemodynamically unstable patients, so the contribution of dopamine in producing this effect is questionable.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bivins BA, Rapp RP, Griffin WO Jr, et al, “Dopamine-Phenytoin Interaction. A Cause of Hypotension in the Critically Ill,” <i>Arch Surg</i>, 1978, 113(3):245-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=637689\">[PubMed 637689]</a></p>\n<p>2. Torres E, Garcia B, Sosa P, et al, “No Interaction Between Dopamine and Phenytoin,” <i>Ann Pharmacother</i>, 1995, 29:1300-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8672843\">[PubMed 8672843]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5837":"<p><b>Title</b> Doxycycline / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Doxycycline. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of doxycycline if used concurrently with phenytoin. Consideration might be given to increasing the dose of doxycycline at the initiation of phenytoin, or use of another tetracycline derivative may be considered to avoid this interaction.</p> \n<p><b>Discussion</b> A comparison of doxycycline half-life in 16 patients on long-term carbamazepine and/or phenytoin therapy revealed a 44-52% shorter half-life compared to controls (mean half-life = 15.1 hours; n=9).<sup>1</sup> For the patients taking phenytoin specifically, the mean doxycycline half-life was 7.2 hours (n=7), and for those taking both carbamazepine and phenytoin, the mean doxycycline half-life was 7.4 hours (n=4). Duration of carbamazepine and/or phenytoin therapy prior to this study was between 4 months and 10 years.<br><br>The suspected mechanism of this potential interaction is induction of doxycycline metabolism or excretion by phenytoin. The specific enzyme(s) and/or transporter(s) involved is uncertain, as most inducers like phenytoin are capable of inducing several metabolic enzymes and transport proteins.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Penttila O, Neuvonen PH, Aho K, et al, “Interaction Between Doxycycline and Some Antiepileptic Drugs,” <i>Br Med J</i>, 1974, 2:470-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4600204\">[PubMed 4600204]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5838":"<p><b>Title</b> Fosphenytoin / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Efavirenz. Efavirenz may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased concentrations and effectiveness of efavirenz when used together with phenytoin. If phenytoin is discontinued, efavirenz concentrations may increase. Also, monitor for increased concentrations (and possible toxicity) of phenytoin when used together with efavirenz. Dose adjustments of one or both agents may be necessary when used in combination.</p> \n<p><b>Discussion</b> A 35-year-old man with a history significant for a partial tonic-clonic seizure disorder that had been well-controlled with phenytoin (400mg twice daily) and pregabalin (150mg twice daily) was started on efavirenz (800mg daily) and emtricitabine/tenofovir (200mg/300mg daily).<sup>1</sup> Three weeks previously, fluconazole (200mg daily) had been started for esophageal candidiasis, necessitating a 50% decrease in phenytoin dose (to 400mg once daily). Blood samples for efavirenz monitoring taken on days 5 and 15 of antiviral therapy both revealed efavirenz concentrations less than 0.5 mcg/mL. As a result, phenytoin was discontinued on day 20 and the efavirenz dose was increased to 600mg twice daily. Efavirenz concentration on day 34 had increased to 3.4 mcg/mL, and the efavirenz dose was reduced to 600mg once daily. Despite the initially low efavirenz concentrations, plasma viral load had decreased from 1,000,000 HIV RNA copies/mL before antiviral therapy to 12,400 copies/mL on day 14. With the higher efavirenz concentration on day 34, viral load fell further to 921 copies/mL.<br><br>Another case report describes a similar experience in which a 39-year-old man receiving phenytoin (300mg twice daily) had efavirenz concentrations of only 0.34 mcg/mL and 0.58 mcg/mL on days 9 and 21 of efavirenz (600mg daily) therapy.<sup>2</sup> After discontinuation of phenytoin and a temporary increase in efavirenz dose (to 800mg daily), the efavirenz concentration rose to 2.5 mcg/mL on day 49. Plasma viral load demonstrated an initial response (even with low efavirenz concentrations), decreasing from 1,816,200 HIV RNA copies/mL before antiviral therapy to 30,863 copies/mL on day 13. With the higher efavirenz concentration, viral load fell further to 189 copies/mL by day 56 of antiviral therapy.<br><br>The probable mechanism for the interactions reported in these cases is phenytoin-mediated induction of efavirenz metabolism.<sup>1,2,3</sup><br><br>Of note, efavirenz was suspected of increasing phenytoin concentrations in one of these cases, with phenytoin concentration increasing from 11.5-13 mg/L to 16.7-23.5 mg/L, despite no changes in phenytoin dose or other changes with concurrent therapy.<sup>2</sup> In vitro studies have shown that efavirenz is an inhibitor of the enzymes principally responsible for phenytoin metabolism (CYP2C9 and CYP2C19) at concentration ranges similar to those normally achieved during therapy.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Spak CW, Dhanireddy S, Kosel BW, “Clinical Interaction between Efavirenz and Phenytoin,” <i>AIDS</i>, 2008, 22(1):164-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18090412\">[PubMed 18090412]</a></p>\n<p>2. Robertson SM, Penzak SR, Lane J, et al, “A Potentially Significant Interaction between Efavirenz and Phenytoin: A Case Report and Review of the Literature,” <i>Clin Infect Dis</i>, 2005, 41:e15-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15983905\">[PubMed 15983905]</a></p>\n<p>3. Prescribing information. Sustiva (efavirenz). Princeton, NJ: Bristol-Myers Squibb, March 2008.</p>\n<p>4. von Moltke LL, Greenblatt DJ, Granda BW, et al, “Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors,” <i>J Clin Pharmacol</i>, 2001, 41(1):85-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11225565\">[PubMed 11225565]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5839":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. If phenytoin must be used in a patient desiring effective birth control, oral contraceptives (and possibly nonoral contraceptives) may not provide adequate protection against conception. Patients must be instructed to use alternative, nonhormonal forms of contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of oral contraceptives, might not be present in spite of the occurrence of an interaction.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Case reports describe women on oral contraceptives who became pregnant during concomitant therapy with oral contraceptives and phenytoin.<sup>1,2</sup> The mechanism of this interaction is unknown, but might be a pharmacokinetic effect related to phenytoin-enhanced metabolism of estrogens and/or progestins. Whether the use of lower dose products carries greater risk of therapeutic failure than higher dose products is unclear. Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kenyon IE, “Unplanned Pregnancy in an Epileptic,” <i>Br Med J</i>, 1972, 1:686. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5015305\">[PubMed 5015305]</a></p>\n<p>2. Janz D and Schmidt D, “Antiepileptic Drugs and Failure of Oral Contraceptives,” <i>Lancet</i>, 1974, i:1113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4135275\">[PubMed 4135275]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5842":"<p><b>Title</b> Etravirine / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Etravirine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use may lead to significantly reduced plasma concentrations of etravirine and potential loss of therapeutic efficacy. The manufacturer of etravirine states this combination should not be used together.</p> \n<p><b>Discussion</b> The manufacturer of etravirine states these drugs should not be used in combination.<sup>1</sup> The mechanism of this interaction is presumably based on the known metabolic CYP450 enzyme induction activity of phenytoin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Intelence (etravirine). Raritan, NJ: Tibotec Therapeutics, January 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5843":"<p><b>Title</b> Fosphenytoin / Felbamate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> A decrease in phenytoin dose will likely be required when adding concurrent felbamate, with some authors suggesting an empiric 20% decrease in phenytoin dose. Additional reductions may be needed if felbamate dose is increased or as otherwise guided by monitoring of phenytoin concentrations and response. Increase monitoring for toxic effects of phenytoin if felbamate is initiated/dose increased, or decreased effects if felbamate is discontinued/dose decreased. Monitor for decreased therapeutic effects of felbamate if phenytoin is initiated/dose increased, or increased effects if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Several reports have described the need to reduce phenytoin dosage by approximately 20% following the addition of felbamate in order to maintain serum phenytoin concentrations at the desired level.<sup>1,2,3,4,5,6</sup> Signs of phenytoin toxicity have been noted. In addition, felbamate clearance has been increased by as much as 40% following the addition of phenytoin.<sup>6,7,8</sup> Clinical effects resulting from such a change are unknown. The mechanisms of these interactions are unknown. Phenytoin likely induces the CYP metabolism of felbamate. Felbamate might inhibit phenytoin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Graves NM, Holmes GB, Fuerst RH, et al, “Effects of Felbamate on Phenytoin and Carbamazepine Serum Concentrations,” <i>Epilepsia</i>, 1989, 30:225-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2647472\">[PubMed 2647472]</a></p>\n<p>2. Fuerst RH, Graves NM, Leppik IE, et al, “A Preliminary Report on Alteration of Carbamazepine and Phenytoin Metabolism by Felbamate,” <i>Drug Intell Clin Pharm</i>, 1986, 20:465-6.</p>\n<p>3. Fuerst RH, Graves NM, Leppik IE, et al, “Felbamate Increases Phenytoin but Decreases Carbamazepine Concentrations,” <i>Epilepsia</i>, 1988, 29:488-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3391153\">[PubMed 3391153]</a></p>\n<p>4. Wilensky AJ, Friel PN, Ojemann LM, et al, “Pharmacokinetics of W-544 (ADD 03055) in Epileptic Patients,” <i>Epilepsia</i>, 1985, 26:602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4076064\">[PubMed 4076064]</a></p>\n<p>5. Sheridan PH, Ashworth M, Milne K, et al, “Open Pilot Study of Felbamate (ADD 03055) in Partial Seizures,” <i>Epilepsia</i>, 1986, 27:649.</p>\n<p>6. Sachdeo R, Wagner ML, Sachdeo S, et al, “Coadministration of Phenytoin and Felbamate: Evidence of Additional Phenytoin Dose-Reduction Requirements Based on Pharmacokinetics and Tolerability with Increasing Doses of Felbamate,” <i>Epilepsia</i>, 1999, 40(8):1122-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10448826\">[PubMed 10448826]</a></p>\n<p>7. Kelley MT, Walson PD, Cox S, et al, “Population Pharmacokinetics of Felbamate in Children,” <i>Ther Drug Monit</i>, 1997, 19:29-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9029743\">[PubMed 9029743]</a></p>\n<p>8. Banfield CR, Zhu GR, Jen JF, et al, “The Effect of Age on the Apparent Clearance of Felbamate: A Retrospective Analysis Using Nonlinear Mixed-Effects Modeling,” <i>Ther Drug Monit</i>, 1996, 18:19-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8848816\">[PubMed 8848816]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5844":"<p><b>Title</b> Fosphenytoin / Floxuridine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Floxuridine may increase the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Phenytoin dose reductions may be necessary when used together with floxuridine. Monitor phenytoin concentrations and response to therapy (both effectiveness and signs/symptoms of toxicity) closely when using this combination.</p> \n<p><b>Discussion</b> Floxuridine is a prodrug of fluorouracil, converted (largely) to fluorouracil in vivo following administration.<sup>1</sup> Several case reports have described phenytoin toxicity associated with concurrent use of floxuridine<sup>2</sup>, fluorouracil<sup>3,4,5</sup> and the fluorouracil prodrugs/analogs capecitabine,<sup>3</sup> and tegafur.<sup>6,7</sup> A study in rats supports these reports, citing up to a 70-75% reduction in phenytoin metabolism in rats given fluorouracil or floxuridine.<sup>8</sup><br><br>The mechanism of this interaction appears to be fluorouracil-mediated inhibition of phenytoin p-hydroxylation, a process normally dependent on CYP2C9. Though neither floxuridine or fluorouracil appear to have any direct inhibitory effect on CYP2C9 in microsomal studies,<sup>8,9</sup> studies in rats and patients with colorectal cancer have demonstrated decreased CYP2C9 activity (i.e., phenytoin hydroxylation<sup>8</sup> and losartan/E3174 ratio<sup>10</sup>) following treatment with both floxuridine<sup>8</sup> and fluorouracil<sup>8,10</sup> treatment. Of note, the inhibition appears time- and/or dose-dependent with greater inhibition after 3 cycles of fluorouracil (5.3-fold decrease) than after 1 cycle (28% decrease).<sup>10</sup> Studies with the CYP2C9 substrate warfarin further support this mechanism.<sup>11,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Floxuridine. Schaumburg, IL: American Pharmaceutical Partners, Inc., June 2002.</p>\n<p>2. Konishi H, Morita K, Minouchi T, et al, “Probable Metabolic Interaction of Doxifluridine with Phenytoin,” <i>Ann Pharmacother</i>, 2002, 36(5):831-4.</p>\n<p>3. Brickell K, Porter D, Thompson P, “Phenytoin Toxicity Due to Fluoropyrimidines (5FU/Capecitabine): Three Case Reports,” <i>Br J Cancer</i>, 2003, 89(4):615-6.</p>\n<p>4. Gilbar PJ, Brodribb TR, “Phenytoin and Fluorouracil Interaction,” <i>Ann Pharmacother</i>, 2001, 35(11):1367-70.</p>\n<p>5. Rosemergy I, Findlay M, “Phenytoin Toxicity as a Result of 5-Fluorouracil Administration,” <i>N Z Med J</i>, 2002, 115(1159):U124.</p>\n<p>6. Tsuda A, Fujiyama J, Miki A, et al, “The First Case of Phenytoin Intoxication Associated with the Concomitant use of Phenytoin and TS-1, a Combination Preparation of Tegafur, Gimeracil, and Oteracil Potassium,” <i>Cancer Chemother Pharmacol</i>, 2008, 62(3):427-32.</p>\n<p>7. Wakisaka S, Shimauchi M, Kaji Y, et al, “Acute Phenytoin Intoxication Associated with the Antineoplastic Agent UFT,” <i>Fukuoka Igaku Zasshi</i>, 1990, 81(4):192-6.</p>\n<p>8. Konishi H, Yoshimoto T, Morita K, et al, “Depression of Phenytoin Metabolic Capacity by 5-Fluorouracil and Doxifluridine in Rats,” <i>J Pharm Pharmacol</i>, 2003, 55(1):143-9.</p>\n<p>9. Park JY, Kim KA, “Inhibitory Effect of 5-Fluorouracil on Human Cytochrome P(450) Isoforms in Human Liver Microsomes,” <i>Eur J Clin Pharmacol</i>, 2003, 59(5-6):407-9.</p>\n<p>10. Gunes A, Coskun U, Boruban C, et al, “Inhibitory Effect of 5-Fluorouracil on Cytochrome P450 2C9 Activity in Cancer Patients,” <i>Basic Clin Pharmacol Toxicol</i>, 2006, 98(2):197-200.</p>\n<p>11. Davis DA, Fugate SE, “Increasing Warfarin Dosage Reductions Associated with Concurrent Warfarin and Repeated Cycles of 5-Fluorouracil Therapy,” <i>Pharmacotherapy</i>, 2005, 25(3):442-7.</p>\n<p>12. Camidge R, Reigner B, Cassidy J, et al, “Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Cancer,” <i>J Clin Oncol</i>, 2005, 23(21):4719-25.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5845":"<p><b>Title</b> Fosphenytoin / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for toxic effects of phenytoin if fluconazole is initiated or the dose is increased. Monitor for decreased therapeutic effects of phenytoin if fluconazole is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC of phenytoin was increased by 75% in normal subjects within approximately 2 weeks of starting fluconazole (200 mg/day).<sup>1</sup> Similarly, phenytoin AUC was increased an average of 33% and the concentration at 48 hrs after a single phenytoin dose was increased an average of 132% when phenytoin (250 mg x1) was given on day 5 of fluconazole (400 mg/day x 6 days) in a study of 9 healthy volunteers.<sup>2</sup> Several cases of phenytoin toxicity associated with fluconazole therapy have also been reported.<sup>3,4,5</sup> In contrast, neither itraconazole nor ketoconazole appear to appreciably alter phenytoin pharmacokinetics.<sup>2,6</sup> A probable mechanism for the fluconazole-phenytoin interaction is inhibition of CYP2C9, resulting in decreased phenytoin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Blum RA, Wilton JH, Hilligoss DM, et al, “Effect of Fluconazole on the Disposition of Phenytoin,” <i>Clin Pharmacol Ther</i>, 1991, 49:420-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2015731\">[PubMed 2015731]</a></p>\n<p>2. Touchette MA, Chandrasekar PH, Milad MA, et al, “Contrasting Effects of Fluconazole and Ketoconazole on Phenytoin and Testosterone Disposition in Man,” <i>Br J Clin Pharmacol</i>, 1992, 34(1):75-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1633070\">[PubMed 1633070]</a></p>\n<p>3. Howitt KM and Oziemski MA, “Phenytoin Toxicity Induced by Fluconazole,” <i>Med J Aust</i>, 1989, 151:603-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2556633\">[PubMed 2556633]</a></p>\n<p>4. Mitchell AS and Holland JT, “Fluconazole and Phenytoin: A Predictable Interaction,” <i>Br Med J</i>, 1989, 298:1315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2544241\">[PubMed 2544241]</a></p>\n<p>5. Cadle RM, Zenon J III, Rodriguez-Barradas C, et al, “Fluconazole-Induced Symptomatic Phenytoin Toxicity,” <i>Ann Pharmacother</i>, 1994, 28:191-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8173131\">[PubMed 8173131]</a></p>\n<p>6. Ducharme MP, Slaughter RL, Warbasse LH, et al, “Itraconazole and Hydroxyitraconazole Serum Concentrations Are Reduced More Than Tenfold by Phenytoin,” <i>Clin Pharmacol Ther</i>, 1995, 58:617-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8529326\">[PubMed 8529326]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5846":"<p><b>Title</b> Flunarizine / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Flunarizine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor effectiveness of flunarizine closely in patients also receiving phenytoin, particularly when increasing or decreasing phenytoin dose.</p> \n<p><b>Discussion</b> Flunarizine clearance following a 30mg single dose in patients receiving the antiepileptic medications phenytoin and/or carbamazepine (phenytoin alone, n=4; carbamazepine alone, n=4; phenytoin and carbamazepine, n=4) was highly variable but averaged about 32% higher than that reported elsewhere for healthy volunteers.<sup>1</sup> Following multiple flunarizine doses, steady-state clearance values were approximately 1.5- to 2.2-fold greater in patients also taking phenytoin and/or carbamazepine than what has been reported for healthy volunteers.<sup>1</sup> This is consistant with lower than anticipated plasma levels of flunarizine that were found when given to epileptic patients taking more than one other drug.<sup>2,3</sup> Despite this apparent interaction, evidence of flunarizine efficacy was still apparent at safe doses, questioning the clinical significance of any interaction.<br><br>The suggested mechanism of this interaction is phenytoin- and/or carbamazepine-mediated induction of flunarizine metabolism,<sup>3</sup> given the known enzyme-inducing properties of these medications. CYP2D6 appears primarily responsible for the oxidative metabolism of flunarizine and is generally considered to be relatively resistant to the inducing effects of drugs, so the precise mechanism of this possible induction-related interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kapetanovic IM, Torchin CD, Kupferberg HJ, et al. Pharmacokinetic profile of flunarizine after single and multiple dosing in epileptic patients receiving comedication. <i>Epilepsia</i>. 1988;29(6):770-774. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3191893\">[PubMed 3191893]</a></p>\n<p>2. Binnie CD, de Beukelaar F, Meijer JW, et al. Open-dose ranging trial of flunarizine as add-on therapy in epilepsy. <i>Epilepsia</i>. 1985;26(5):424-428. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3899624\">[PubMed 3899624]</a></p>\n<p>3. Product monograph. Flunarizine. Toronto, Ontario, Canada: AA Pharma Inc., May 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5848":"<p><b>Title</b> Fosphenytoin / Fluorouracil (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluorouracil (Systemic) may increase the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Phenytoin dose reductions may be necessary when used together with fluorouracil. Monitor phenytoin concentrations and response to therapy (both effectiveness and signs/symptoms of toxicity) closely when using this combination.</p> \n<p><b>Discussion</b> Several case reports have described phenytoin toxicity associated with concurrent use of fluorouracil<sup>1,2,3</sup> and the fluorouracil prodrugs/analogs capecitabine,<sup>1</sup> floxuridine,<sup>4</sup>, and tegafur.<sup>5,6</sup> A study in rats supports these reports, citing up to a 70-75% reduction in phenytoin metabolism in rats given fluorouracil or floxuridine.<sup>7</sup><br><br>The mechanism of this interaction appears to be fluorouracil-mediated inhibition of phenytoin p-hydroxylation, a process normally dependent on CYP2C9. Though neither floxuridine or fluorouracil appear to have any direct inhibitory effect on CYP2C9 in microsomal studies,<sup>7,8</sup> studies in rats and patients with colorectal cancer have demonstrated decreased CYP2C9 activity (i.e., phenytoin hydroxylation<sup>7</sup> and losartan/E3174 ratio<sup>9</sup>) following treatment with both floxuridine<sup>7</sup> and fluorouracil<sup>7,9</sup> treatment. Of note, the inhibition appears time- and/or dose-dependent with greater inhibition after 3 cycles of fluorouracil (5.3-fold decrease) than after 1 cycle (28% decrease).<sup>9</sup> Studies with the CYP2C9 substrate warfarin further support this.<sup>10,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Brickell K, Porter D, Thompson P, “Phenytoin Toxicity Due to Fluoropyrimidines (5FU/Capecitabine): Three Case Reports,” <i>Br J Cancer</i>, 2003, 89(4):615-6.</p>\n<p>2. Gilbar PJ, Brodribb TR, “Phenytoin and Fluorouracil Interaction,” <i>Ann Pharmacother</i>, 2001, 35(11):1367-70.</p>\n<p>3. Rosemergy I, Findlay M, “Phenytoin Toxicity as a Result of 5-Fluorouracil Administration,” <i>N Z Med J</i>, 2002, 115(1159):U124.</p>\n<p>4. Konishi H, Morita K, Minouchi T, et al, “Probable Metabolic Interaction of Doxifluridine with Phenytoin,” <i>Ann Pharmacother</i>, 2002, 36(5):831-4.</p>\n<p>5. Tsuda A, Fujiyama J, Miki A, et al, “The First Case of Phenytoin Intoxication Associated with the Concomitant use of Phenytoin and TS-1, a Combination Preparation of Tegafur, Gimeracil, and Oteracil Potassium,” <i>Cancer Chemother Pharmacol</i>, 2008, 62(3):427-32.</p>\n<p>6. Wakisaka S, Shimauchi M, Kaji Y, et al, “Acute Phenytoin Intoxication Associated with the Antineoplastic Agent UFT,” <i>Fukuoka Igaku Zasshi</i>, 1990, 81(4):192-6.</p>\n<p>7. Konishi H, Yoshimoto T, Morita K, et al, “Depression of Phenytoin Metabolic Capacity by 5-Fluorouracil and Doxifluridine in Rats,” <i>J Pharm Pharmacol</i>, 2003, 55(1):143-9.</p>\n<p>8. Park JY, Kim KA, “Inhibitory Effect of 5-Fluorouracil on Human Cytochrome P(450) Isoforms in Human Liver Microsomes,” <i>Eur J Clin Pharmacol</i>, 2003, 59(5-6):407-9.</p>\n<p>9. Gunes A, Coskun U, Boruban C, et al, “Inhibitory Effect of 5-Fluorouracil on Cytochrome P450 2C9 Activity in Cancer Patients,” <i>Basic Clin Pharmacol Toxicol</i>, 2006, 98(2):197-200.</p>\n<p>10. Davis DA, Fugate SE, “Increasing Warfarin Dosage Reductions Associated with Concurrent Warfarin and Repeated Cycles of 5-Fluorouracil Therapy,” <i>Pharmacotherapy</i>, 2005, 25(3):442-7.</p>\n<p>11. Camidge R, Reigner B, Cassidy J, et al, “Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Cancer,” <i>J Clin Oncol</i>, 2005, 23(21):4719-25.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5849":"<p><b>Title</b> Fosphenytoin / Fluorouracil (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fluorouracil (Topical) may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor phenyoin concentrations and response to therapy (both effectiveness and signs/symptoms of toxicity) when starting or stopping topical fluorouracil. Phenytoin dose reductions may be necessary.</p> \n<p><b>Discussion</b> Several case reports have described phenytoin toxicity associated with concurrent use of fluorouracil<sup>1,2,3</sup> and the fluorouracil prodrugs/analogs capecitabine,<sup>1</sup> floxuridine,<sup>4</sup>, and tegafur.<sup>5,6</sup> A study in rats supports these reports, citing up to a 70-75% reduction in phenytoin metabolism in rats given fluorouracil or floxuridine.<sup>7</sup><br><br>Per Efudex prescribing information, approximately 6% of a fluorouracil dose is systemically absorbed from a 5% topical preparation (i.e. approximately 3 mg absorbed per gram of cream applied).<sup>8</sup> This generally corresponds to several fold lower systemic doses than typical intravenous chemotherapy. However, reports of systemic adverse events during topical fluorouracil treatment suggest that some systemic drug interactions may be significant even with topical administration.<sup>8,9</sup> <br><br>The mechanism of this interaction appears to be fluorouracil-mediated inhibition of phenytoin p-hydroxylation, a process normally dependent on CYP2C9. Though neither floxuridine or fluorouracil appear to have any direct inhibitory effect on CYP2C9 in microsomal studies,<sup>9,10</sup> studies in rats and patients with colorectal cancer have demonstrated decreased CYP2C9 activity (i.e., phenytoin hydroxylation<sup>7</sup> and losartan/E3174 ratio<sup>11</sup>) following treatment with both floxuridine<sup>7</sup> and fluorouracil<sup>7,11</sup> treatment. Of note, the inhibition appears time- and/or dose-dependent with greater inhibition after 3 cycles of fluorouracil (5.3-fold decrease) than after 1 cycle (28% decrease).<sup>11</sup> Studies with the CYP2C9 substrate warfarin further support this mechanism.<sup>12,13</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Brickell K, Porter D, Thompson P, “Phenytoin Toxicity Due to Fluoropyrimidines (5FU/Capecitabine): Three Case Reports,” <i>Br J Cancer</i>, 2003, 89(4):615-6.</p>\n<p>2. Gilbar PJ, Brodribb TR, “Phenytoin and Fluorouracil Interaction,” <i>Ann Pharmacother</i>, 2001, 35(11):1367-70.</p>\n<p>3. Rosemergy I, Findlay M, “Phenytoin Toxicity as a Result of 5-Fluorouracil Administration,” <i>N Z Med J</i>, 2002, 115(1159):U124.</p>\n<p>4. Konishi H, Morita K, Minouchi T, et al, “Probable Metabolic Interaction of Doxifluridine with Phenytoin,” <i>Ann Pharmacother</i>, 2002, 36(5):831-4.</p>\n<p>5. Tsuda A, Fujiyama J, Miki A, et al, “The First Case of Phenytoin Intoxication Associated with the Concomitant use of Phenytoin and TS-1, a Combination Preparation of Tegafur, Gimeracil, and Oteracil Potassium,” <i>Cancer Chemother Pharmacol</i>, 2008, 62(3):427-32.</p>\n<p>6. Wakisaka S, Shimauchi M, Kaji Y, et al, “Acute Phenytoin Intoxication Associated with the Antineoplastic Agent UFT,” <i>Fukuoka Igaku Zasshi</i>, 1990, 81(4):192-6.</p>\n<p>7. Konishi H, Yoshimoto T, Morita K, et al, “Depression of Phenytoin Metabolic Capacity by 5-Fluorouracil and Doxifluridine in Rats,” <i>J Pharm Pharmacol</i>, 2003, 55(1):143-9.</p>\n<p>8. Prescribing information. Efudex (fluorouracil). Costa Mesa, CA: ICN Pharmaceuticals, Inc, October 2005.</p>\n<p>9. Prescribing information. Carac (fluorouracil). Bridgewater, NJ: Dermik Laboratories, November 2006.</p>\n<p>10. Park JY, Kim KA, “Inhibitory Effect of 5-Fluorouracil on Human Cytochrome P(450) Isoforms in Human Liver Microsomes,” <i>Eur J Clin Pharmacol</i>, 2003, 59(5-6):407-9.</p>\n<p>11. Gunes A, Coskun U, Boruban C, et al, “Inhibitory Effect of 5-Fluorouracil on Cytochrome P450 2C9 Activity in Cancer Patients,” <i>Basic Clin Pharmacol Toxicol</i>, 2006, 98(2):197-200.</p>\n<p>12. Davis DA, Fugate SE, “Increasing Warfarin Dosage Reductions Associated with Concurrent Warfarin and Repeated Cycles of 5-Fluorouracil Therapy,” <i>Pharmacotherapy</i>, 2005, 25(3):442-7.</p>\n<p>13. Camidge R, Reigner B, Cassidy J, et al, “Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Cancer,” <i>J Clin Oncol</i>, 2005, 23(21):4719-25.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5850":"<p><b>Title</b> FLUoxetine / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may enhance the QTc-prolonging effect of FLUoxetine. FLUoxetine may increase the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Any use of fosphenytoin and fluoxetine in combination should be undertaken with caution, and should be avoided when possible. Concomitant use may substantially increase the risk for serious toxicities, including torsades de pointes or other significant ventricular tachyarrhythmias. Patients with other risk factors present (e.g., older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations), would be at an even higher risk for these potentially life-threatening toxicities. The use of this combination should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm, as well as for increased concentrations and general toxicity of phenytoin.</p> \n<p><b>Discussion</b> Serum phenytoin concentrations have been noted to increase by 60% to 400% within 10 days of initiating fluoxetine therapy.<sup>1,2</sup> Several case reports have described development of symptoms of phenytoin toxicity with this combination.<sup>3,4</sup> Additionally, discontinuation of fluoxetine in a phenytoin-maintained patient resulted in a 58% reduction in total phenytoin concentration.<sup>5</sup> <br><br>The likely primary mechanism of pharmacokinetic interaction between these agents is fluoxetine inhibition of CYP2C19 and/or 2C9 mediated phenytoin metabolism. In addition to the potential for increased phenytoin concentrations with this combination, both drugs have the capacity to prolong QTc interval, and their combination may consequently increase the risk of torsades de pointes or other significant ventricular tachyarrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Woods DJ, Coulter DM, and Pillans P, “Interaction of Phenytoin and Fluoxetine,” <i>N Z Med J</i>, 1994, 107:970. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8295752\">[PubMed 8295752]</a></p>\n<p>2. Jalil P, “Toxic Reaction Following the Combined Administration of Fluoxetine and Phenytoin: Two Case Reports,” <i>J Neurol Neurosurg Psychiat</i>, 1992, 55:412-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1602320\">[PubMed 1602320]</a></p>\n<p>3. Darley J, “Interaction Between Phenytoin and Fluoxetine,” <i>Seizure</i>, 1994 Jun;3(2):151-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8081642\">[PubMed 8081642]</a></p>\n<p>4. Shader RI, Greenblatt DJ and von Moltke LL, “Fluoxetine Inhibition of Phenytoin Metabolism,” <i>J Clin Psychopharmacol</i>, 1994, 14(6):375-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7884016\">[PubMed 7884016]</a></p>\n<p>5. Shad MU and Preskorn SH, “Drug-Drug Interaction in Reverse: Possible Loss of Phenytoin Efficacy as a Result of Fluoxetine Discontinuation,” <i>J Clin Psychopharmacol</i>, 1999, 19(5):471-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10505590\">[PubMed 10505590]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5851":"<p><b>Title</b> Fosphenytoin / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased concentrations/toxic effects of phenytoin if fluvoxamine is initiated/dose increased, or decreased concentrations/effects if fluvoxamine is discontinued/dose decreased. Adjust phenytoin dose as needed.</p> \n<p><b>Discussion</b> A case report describes a patient whose phenytoin serum concentration increased roughly 3 fold following initiation of fluvoxamine.<sup>1</sup> Genotyping detected no CYP2C9 or 2C19 loss of function variants. The likely primary mechanism of interaction between these agents is fluvoxamine inhibition of CYP2C19 mediated phenytoin metabolism. Fluvoxamine inhibition of CYP2C9 may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mamiya K, Kojima K, Yukawa E, et al, “Phenytoin Intoxication Induced by Fluvoxamine,” <i>Ther Drug Monit</i>, 2001, 23(1):75-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11206048\">[PubMed 11206048]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5852":"<p><b>Title</b> Fosphenytoin / Folic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Folic Acid may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and effectiveness of phenytoin if folic acid is initiated/dose increased. Similarly, monitor for increases in phenytoin concentrations (and possible toxicity) if folic acid is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Serum phenytoin concentrations decreased 30% to 50% in 50 patients within one month of initiating folic acid therapy.<sup>1</sup> In small case series reports and individual case reports, the addition of folic acid at doses of 1mg have been associated with 20-23% reductions in phenytoin concentrations,<sup>2,3</sup> while addition of 5mg doses have been associated with 40-60% reductions in phenytoin concentrations.<sup>4,5</sup> Similar reductions in serum phenytoin concentrations have been reported elsewhere.<sup>6,7,8</sup> Several reports have also described an apparent lack of effectiveness following the addition of folic acid, with reports of breakthrough seizures and/or an increase in seizure episodes.<sup>1,2,5,9,10</sup><br><br>Though the detailed mechanism of this interaction has yet to be fully described, folic acid appears to function as a cofactor in the metabolism of phenytoin, with reports that higher folic acid concentration increase the affinity (i.e., decreased Km) of metabolizing enzymes for phenytoin.<sup>2,3,9,10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Baylis EM, Crowley JM, Preece JM, et al, “Influence of Folic Acid on Blood-Phenytoin Levels,” <i>Lancet</i>, 1971 i:62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4099219\">[PubMed 4099219]</a></p>\n<p>2. Berg MJ, Fisher LJ, Rivey MP, et al, “Phenytoin and Folic Acid Interaction: A Preliminary Report,” <i>Ther Drug Monit</i>, 1983, 5:389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659012\">[PubMed 6659012]</a></p>\n<p>3. Berg MJ, Ebert BE, Rivey MP, et al, “Utilization of Km for Phenytoin Dosage After Folate Addition to Patient Regimen,” <i>Ther Drug Monit</i>, 1987, 9:304-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3672574\">[PubMed 3672574]</a></p>\n<p>4. Inoue F, Kolabinski I, “Possible Interaction Between Phenytoin Therapy and Folate Supplement: Two Case Reports,” <i>Can J Hosp Pharm</i>, 1986, 39:16-8.</p>\n<p>5. Steinweg DL, Bentley ML, “Seizures Following Reduction in Phenytoin Level After Orally Administered Folic Acid,” <i>Neurology</i>, 2005, 64(11):1982. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955964\">[PubMed 15955964]</a></p>\n<p>6. Glazko AJ, “Antiepileptic Drugs: Biotransformation, Metabolism, and Serum Half-Life,” <i>Epilepsia</i>, 1975, 16:367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=238831\">[PubMed 238831]</a></p>\n<p>7. Jensen ON and Olesen OV, “Subnormal Serum Folate Due to Anticonvulsive Therapy. A Double-Blind Study of the Effect of Folic Acid Treatment in Patients With Drug-Induced Subnormal Serum Folates,” <i>Arch Neurol</i>, 1970, 22:181-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4902774\">[PubMed 4902774]</a></p>\n<p>8. Furlanut M, Benetello P, Avogaro A, et al, “Effects of Folic Acid on Phenytoin Kinetics in Healthy Subjects,” <i>Clin Pharmacol Ther</i>, 1978, 24:294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=688723\">[PubMed 688723]</a></p>\n<p>9. Berg MJ, Rivey MP, Vern BA, et al, “Phenytoin and Folic Acid: Individualized Drug-Drug Interaction,” <i>Ther Drug Monit</i>, 1983, 5:395-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659013\">[PubMed 6659013]</a></p>\n<p>10. Seligmann H, Potasman I, Weller B, et al, “Phenytoin-Folic Acid Interaction: A Lesson to be Learned,” <i>Clin Neuropharmacol</i>, 1999, 22(5):268-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10516876\">[PubMed 10516876]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5853":"<p><b>Title</b> Fosphenytoin / Fosamprenavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may increase the serum concentration of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to both fosamprenavir and phenytoin when using these agents in combination, and particularly when starting, stopping, or altering dosing of one or both agents. Monitor plasma phenytoin concentrations closely when applicable, and consider monitoring free (unbound) phenytoin concentrations since the interaction may involve protein binding displacement.</p> \n<p><b>Discussion</b> According to fosamprenavir prescribing information, amprenavir AUC and minimum concentration (Cmin) were both increased by approximately 20% with combined phenytoin (300mg daily x 10 days) and fosamprenavir/ritonavir (700mg/100mg twice daily x 10 days) in a study of 13 individuals.<sup>1</sup> Amprenavir maximum concentration (Cmax) was not significantly altered with the combination. Conversely, the phenytoin AUC, Cmax, and Cmin were all approximately 20-30% lower with the phenytoin-fosamprenavir/ritonavir combination.<sup>1</sup><br><br>The mechanism(s) responsible for these observed changes is/are unclear. All of the drugs involved are known to have substantial effects on the cytochrome P450 enzymes, as inhibitors and/or inducers. Fosamprenavir/ritonavir are also highly bound to plasma proteins, and protein binding displacement by fosamprenavir/ritonavir has been implicated in at least one other interaction where total concentrations of the affected drug were reduced.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, October 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5854":"<p><b>Title</b> Fosphenytoin / Immune Globulins</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Immune Globulins may enhance the adverse/toxic effect of Fosphenytoin. Specifically the development of hypersensitivity myocarditis. <b>Severity</b> Major <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for evidence of hypersensitivity myocarditis during concomitant administration of an immune globulin and phenytoin.</p>\n<div>\n <p><b>Immune Globulins Interacting Members</b> Anthrax Immune Globulin (Human), Antithymocyte Globulin (Equine), Botulism Immune Globulin (Intravenous-Human), Cytomegalovirus Immune Globulin (Intravenous-Human), Hepatitis B Immune Globulin (Human), Immune Globulin, Rabies Immune Globulin (Human), Respiratory Syncytial Virus Immune Globulin (Intravenous), Rho(D) Immune Globulin, Tetanus Immune Globulin (Human), Vaccinia Immune Globulin (Intravenous), Varicella-Zoster Immune Globulin (Human)</p>\n</div> \n<p><b>Discussion</b> Case report. A phenytoin patient (also receiving nizatidine and acetaminophen) was administered a 5-day course of IV immune globulin (IVIG) for treatment of Guillain-Barre syndrome. He developed aching shoulders and back, abdominal pain, and hypotension, and subsequently died. Autopsy revealed hypersensitivity myocarditis.<sup>1</sup> Phenytoin has been associated with hypersensitivity myocarditis. Whether or not IVIG administration affected its clinical course is unknown. Causal relationship has not been established.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Koehler PJ and Koudstaal J, “Lethal Hypersensitivity Myocarditis Associated With the Use of Intravenous Gamma Globulin for Guillain-Barre Syndrome in Combination With Phenytoin,” <i>J Neurol</i>, 1996, 243:366-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8965113\">[PubMed 8965113]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5856":"<p><b>Title</b> Fosphenytoin / Isoniazid</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Isoniazid may increase the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to isoniazid in patients receiving phenytoin. If concomitant therapy cannot be avoided, monitor for increased concentrations/toxic effects of phenytoin if isoniazid is initiated/dose increased, or decreased concentrations/effects if isoniazid is discontinued/dose decreased. Heightened monitoring should continue for at least 4 weeks after changes in isoniazid therapy.</p> \n<p><b>Discussion</b> Serum phenytoin concentrations, as well as signs and symptoms of toxicity, have been increased following the initiation of isoniazid therapy in a number of patients and healthy volunteers.<sup>1,2,3,4,5</sup> This interaction has occurred within days of isoniazid initiation in some cases, and up to several weeks after treatment initiation in others.<br> <br>The likely primary mechanism of this interaction is isoniazid inhibition of CYP2C19 mediated phenytoin metabolism. Isoniazid inhibition of CYP2C9 and 3A4 could also contribute. The magnitude of this interaction seems to be greater in individuals with impaired isoniazid metabolism, presumably due to elevated isoniazid concentrations, but determinants of this metabolic impairment are not well understood.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kutt H, Brennan R, Dehejia H, et al, “Diphenylhydantoin Intoxication, A Complication of Isoniazid Therapy,” <i>Am Rev Respir Dis</i>, 1970, 101(3):377-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5414058\">[PubMed 5414058]</a></p>\n<p>2. Brennan RW, Dehejia H, Kutt H, et al, “Diphenylhydantoin Intoxication Attendant to Slow Inactivation of Isoniazid,” <i>Neurology</i>, 1970, 20(7):687-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5463537\">[PubMed 5463537]</a></p>\n<p>3. Murray FJ, “Outbreak of Unexpected Reactions Among Epileptics Taking Isoniazid,” <i>Am Rev Respir Dis</i>, 1962, 86:729-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13936763\">[PubMed 13936763]</a></p>\n<p>4. Miller RR, Porter J and Greenblatt DJ, “Clinical Importance of the Interaction of Phenytoin and Isoniazid: A Report From the Boston Collaborative Drug Surveillance Program,” <i>Chest</i>, 1979, 75(3):356-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=421578\">[PubMed 421578]</a></p>\n<p>5. Witmer DR and Ritschel WA, “Phenytoin-Isoniazid Interaction: A Kinetic Approach to Management,” <i>Drug Intell Clin Pharm</i>, 1984, 18(6):483-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6734435\">[PubMed 6734435]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5857":"<p><b>Title</b> Lacosamide / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Lacosamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased lacosamide levels/effects with phenytoin initiation/dose increase. Conversely, monitor for increased lacosamide levels/effects with phenytoin discontinuation/dose decrease.</p> \n<p><b>Discussion</b> According to lacosamide prescribing information, population pharmacokinetic data from patients with partial onset-seizures suggest that lacosamide serum concentrations may be decreased by 15-20% with concomitant carbamazepine, phenytoin, or phenobarbital therapy.<sup>1</sup> Conversely, lacosamide therapy had no affect on phenytoin levels. The clinical significance of this possible interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Vimpat (lacosamide). Smyrna, GA: UCB, Inc., October 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5858":"<p><b>Title</b> LamoTRIgine / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of LamoTRIgine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The manufacturer of lamotrigine has published extensive dosage adjustment guidelines in the approved labeling when the drug is added to an enzyme-inducing antiepileptic drug (AIAED); refer to the labeling for additional information. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if phenytoin is initiated/dose increased, or increased effects if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The half-life of lamotrigine, as monotherapy, is approximately 25 hours (<u>+</u> 10 hours).<sup>1</sup> When combined with metabolic induction agents, such as phenytoin, the half-life is reduced to approximately 14 hours (<u>+</u> 7 hours).<sup>2</sup> Phenytoin likely stimulates hepatic metabolism of lamotrigine, possibly by stimulating uridine glucuronosyl transferase (UGT). Serum lamotrigine concentrations are thus decreased.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cohen AF, Land GS, Breimer DD, et al, “Lamotrigine, A New Anticonvulsant: Pharmacokinetics in Normal Humans,” <i>Clin Pharmacol Ther</i>, 1987, 41:535-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3677592\">[PubMed 3677592]</a></p>\n<p>2. Binnie CD, Debets RM, Engelsman M, et al, “Double Blind Crossover Trial of Lamotrigine (Lamictal) as Add-On Therapy in Intractable Epilepsy,” <i>Epilepsy Res</i>, 1989, 4(3):222-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2612495\">[PubMed 2612495]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5859":"<p><b>Title</b> Fosphenytoin / Leucovorin Calcium-Levoleucovorin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and effectiveness of phenytoin if leucovorin calcium or levoleucovorin is initiated/dose increased. Similarly, monitor for increases in phenytoin concentrations (and possible toxicity) if leucovorin calcium or levoleucovorin is discontinued/dose decreased.</p>\n<div>\n <p><b>Leucovorin Calcium-Levoleucovorin Interacting Members</b> Leucovorin Calcium, LEVOleucovorin</p>\n</div> \n<p><b>Discussion</b> One case report describes evidence of decreased phenytoin effectiveness that coincided with initiation of therapy with leucovorin calcium (calcium folinate), tegafur, and uracil.<sup>1</sup> Due largely to existing data that support a folic acid-phenytoin interaction resulting in lower phenytoin concentrations and resultant loss of phenytoin effectiveness, the leucovorin calcium was primarily implicated in this case.<br><br>Concurrent folic acid has been associated with 20-60% decreases in serum phenytoin concentrations and a loss of clinical effectiveness in a variety of studies and case reports.<sup>2,3,4,5,6</sup> Though the detailed mechanism of this interaction has yet to be fully described, folic acid appears to function as a cofactor in the metabolism of phenytoin, with reports that higher folic acid concentration increase the affinity (i.e., decreased Km) of metabolizing enzymes for phenytoin.<sup>3,4</sup> It is suspected that any leucovorin calcium/levoleucovorin interaction with phenytoin would occur via an identical mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Veldhorst-Janssen NML, Boersma HH, de Krom MCFM, et al, “Oral Tegafur/Folinic Acid Chemotherapy Decreases Phenytoin Efficacy,” <i>Br J Cancer</i>, 2004, 90:745. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14760393\">[PubMed 14760393]</a></p>\n<p>2. Baylis EM, Crowley JM, Preece JM, et al, “Influence of Folic Acid on Blood-Phenytoin Levels,” <i>Lancet</i>, 1971 i:62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4099219\">[PubMed 4099219]</a></p>\n<p>3. Berg MJ, Fisher LJ, Rivey MP, et al, “Phenytoin and Folic Acid Interaction: A Preliminary Report,” <i>Ther Drug Monit</i>, 1983, 5:389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659012\">[PubMed 6659012]</a></p>\n<p>4. Berg MJ, Ebert BE, Rivey MP, et al, “Utilization of Km for Phenytoin Dosage After Folate Addition to Patient Regimen,” <i>Ther Drug Monit</i>, 1987, 9:304-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3672574\">[PubMed 3672574]</a></p>\n<p>5. Inoue F, Kolabinski I, “Possible Interaction Between Phenytoin Therapy and Folate Supplement: Two Case Reports,” <i>Can J Hosp Pharm</i>, 1986, 39:16-8.</p>\n<p>6. Steinweg DL, Bentley ML, “Seizures Following Reduction in Phenytoin Level After Orally Administered Folic Acid,” <i>Neurology</i>, 2005, 64(11):1982. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955964\">[PubMed 15955964]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5860":"<p><b>Title</b> Levodopa / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may diminish the therapeutic effect of Levodopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of levodopa if phenytoin is initiated/dose increased, or increased effects/toxicity if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The therapeutic (anti-Parkinson) effects of levodopa were essentially abolished in 5 patients within several days of initiating phenytoin (100-500 mg/day) for the treatment of levodopa-induced dyskinesias.<sup>1</sup> Levodopa doses were 630-4600 mg/day (plus carbidopa 150-225 mg/day). The effectiveness of levodopa was evident again within 2 weeks of discontinuing the phenytoin.<br><br>In another study (n=5), concurrent use of phenytoin with levodopa was associated with an increased growth hormone and prolactin response to levodopa.<sup>2</sup> In fact, plasma phenytoin concentrations were correlated with the measured growth hormone response.<br><br>Though the specific mechanism and nature of this potential interaction remains uncertain, available data suggest that phenytoin can alter dopaminergic signalling in the central nervous system in a region-specific manner (i.e., increasing dopamine signalling in some regions and decreasing such activity in other regions).<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mendez JS, Cotzias GC, Mena I, et al, “Diphenylhydantoin. Blocking of Levodopa Effects,” <i>Arch Neurol</i>, 1975, 32(1):44-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=123156\">[PubMed 123156]</a></p>\n<p>2. D'Alessandro R, Cortelli P, Gallassi R, et al, “Phenytoin-Induced Increase in Growth Hormone Response to Levodopa in Adult Males,” <i>J Neurol Neurosurg Psychiatry</i>, 1984, 47(7):715-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6431057\">[PubMed 6431057]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5861":"<p><b>Title</b> Fosphenytoin / Levomefolate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Levomefolate may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and effectiveness of phenytoin if levomefolate is initiated/dose increased. Similarly, monitor for increases in phenytoin concentrations (and possible toxicity) if levomefolate is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Levomefolate (L-5-methyl-tetrahydrofolate) is the primary dietary and circulating form of folic acid. Though specific data regarding concurrent use of levomefolate and methotrexate are not available, levomefolate prescribing information cautions that folates such as levomefolate may alter the response to some drugs, such as phenytoin.<sup>1</sup><br><br>Serum phenytoin concentrations decreased 30% to 50% in 50 patients within one month of initiating folic acid therapy.<sup>2</sup> In small case series reports and individual case reports, the addition of folic acid at doses of 1mg have been associated with 20-23% reductions in phenytoin concentrations,<sup>3,4</sup> while addition of 5mg doses have been associated with 40-60% reductions in phenytoin concentrations.<sup>5,6</sup> Similar reductions in serum phenytoin concentrations have been reported elsewhere.<sup>7,8,9</sup> Several reports have also described an apparent lack of effectiveness following the addition of folic acid, with reports of breakthrough seizures and/or an increase in seizure episodes.<sup>2,3,6,10,11</sup><br><br>Though the detailed mechanism of this interaction has yet to be fully described, folic acid appears to function as a cofactor in the metabolism of phenytoin, with reports that higher folic acid concentration increase the affinity (i.e., decreased Km) of metabolizing enzymes for phenytoin.<sup>3,4,10,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Beyaz (drospirenone/ethinyl estradiol/ levomefolate calcium tablets and levomefolate calcium tablets). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 9/2010.</p>\n<p>2. Baylis EM, Crowley JM, Preece JM, et al, “Influence of Folic Acid on Blood-Phenytoin Levels,” <i>Lancet</i>, 1971 i:62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4099219\">[PubMed 4099219]</a></p>\n<p>3. Berg MJ, Fisher LJ, Rivey MP, et al, “Phenytoin and Folic Acid Interaction: A Preliminary Report,” <i>Ther Drug Monit</i>, 1983, 5:389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659012\">[PubMed 6659012]</a></p>\n<p>4. Berg MJ, Ebert BE, Rivey MP, et al, “Utilization of Km for Phenytoin Dosage After Folate Addition to Patient Regimen,” <i>Ther Drug Monit</i>, 1987, 9:304-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3672574\">[PubMed 3672574]</a></p>\n<p>5. Inoue F, Kolabinski I, “Possible Interaction Between Phenytoin Therapy and Folate Supplement: Two Case Reports,” <i>Can J Hosp Pharm</i>, 1986, 39:16-8.</p>\n<p>6. Steinweg DL, Bentley ML, “Seizures Following Reduction in Phenytoin Level After Orally Administered Folic Acid,” <i>Neurology</i>, 2005, 64(11):1982. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955964\">[PubMed 15955964]</a></p>\n<p>7. Glazko AJ, “Antiepileptic Drugs: Biotransformation, Metabolism, and Serum Half-Life,” <i>Epilepsia</i>, 1975, 16:367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=238831\">[PubMed 238831]</a></p>\n<p>8. Jensen ON and Olesen OV, “Subnormal Serum Folate Due to Anticonvulsive Therapy. A Double-Blind Study of the Effect of Folic Acid Treatment in Patients With Drug-Induced Subnormal Serum Folates,” <i>Arch Neurol</i>, 1970, 22:181-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4902774\">[PubMed 4902774]</a></p>\n<p>9. Furlanut M, Benetello P, Avogaro A, et al, “Effects of Folic Acid on Phenytoin Kinetics in Healthy Subjects,” <i>Clin Pharmacol Ther</i>, 1978, 24:294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=688723\">[PubMed 688723]</a></p>\n<p>10. Berg MJ, Rivey MP, Vern BA, et al, “Phenytoin and Folic Acid: Individualized Drug-Drug Interaction,” <i>Ther Drug Monit</i>, 1983, 5:395-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659013\">[PubMed 6659013]</a></p>\n<p>11. Seligmann H, Potasman I, Weller B, et al, “Phenytoin-Folic Acid Interaction: A Lesson to be Learned,” <i>Clin Neuropharmacol</i>, 1999, 22(5):268-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10516876\">[PubMed 10516876]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5862":"<p><b>Title</b> Lithium / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may enhance the adverse/toxic effect of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of lithium-associated toxicity if lithium and phenytoin are used concomitantly. Lithium toxicity may occur without any apparent increase in lithium concentrations.</p> \n<p><b>Discussion</b> Three case reports describe the development of typical signs and symptoms of lithium intoxication that developed during concomitant therapy with phenytoin, and without any apparent increase in lithium concentrations.<sup>1,2,3</sup> A cause-effect relationship has not been established and, therefore, nor has a mechanism for the possible interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Spiers J and Hirsch SR, “Severe Lithium Toxicity With Normal Serum Concentrations,” <i>Br Med J</i>, 1978, 1:185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=638462\">[PubMed 638462]</a></p>\n<p>2. MacCallum WA, “Interaction of Lithium and Phenytoin,” <i>Br Med J</i>, 1980, 280:10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7370605\">[PubMed 7370605]</a></p>\n<p>3. Salem RB, Director K, and Muniz CE, “Ataxia as the Primary Symptom of Lithium Toxicity,” <i>Drug Intell Clin Pharm</i>, 1980, 14:622.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5863":"<p><b>Title</b> Lopinavir / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Lopinavir. Lopinavir may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Dose adjustments of phenytoin and/or lopinavir may be necessary when using these agents in combination. The manufacturer of lopinavir/ritonavir recommends avoiding once-daily administration if used together with phenytoin. Increased monitoring of therapeutic response to both agents together with close monitoring of phenytoin concentrations is recommended, particularly with any dose increases or decreases.</p> \n<p><b>Discussion</b> Concurrent lopinavir/ritonavir (400mg/100mg twice daily) and phenytoin (300mg daily) for 11 days (n=24) was associated with a 30% lower lopinavir AUC, a 35% lower ritonavir AUC, and a 23% lower phenytoin AUC.<sup>1</sup> Minimum and maximum concentrations of all three agents were also substantially (20-50%) lower during combined therapy.<br><br>The mechanism(s) of this multi-agent interaction remain(s) unclear. Similarly, the degree to which lopinavir and/or ritonavir contribute to the interaction is not known. Both lopinavir/ritonavir and phenytoin are known inducers of drug metabolism, which could at least partially explain the observed effects.<sup>1,2</sup> Induction of drug transport and protein binding displacement are other mechanisms that may contribute to the interaction.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lim ML, Min SS, Eron JJ, et al, “Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction through Cytochrome P-450 Induction,” <i>J Acquir Immune Defic Syndr</i>, 2004, 36:1034-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15247556\">[PubMed 15247556]</a></p>\n<p>2. Prescribing information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, 11/2007.</p>\n<p>3. van der Lee MJ, Blenke AA, Rongen GA, et al, “Interaction Study of the Combined Use of Paroxetine and Fosamprenavir-Ritonavir in Healthy Subjects,” <i>Antimicrob Agents Chemother</i>, 2007, 51:4098-104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17846135\">[PubMed 17846135]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5864":"<p><b>Title</b> Mebendazole / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Mebendazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of mebendazole if phenytoin is initiated/dose increased, especially if mebendazole is being used to treat infections in tissues affected by serum drug concentrations (versus GI tract infections). Mebendazole dose increases might become necessary.</p> \n<p><b>Discussion</b> A single report describes decreases in serum mebendazole concentrations presumably due to phenytoin therapy.<sup>1</sup> It is suggested that this interaction would likely only be of concern when treating infections within tissues, as opposed to GI infections. Mebendazole dose increases might become necessary. The mechanism of this presumed interaction is thought to be phenytoin-mediated induction of mebendazole metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Luder PJ, Siffert B, Witassek F, et al, “Treatment of Hydatid Disease With High Oral Doses of Mebendazole. Long-Term Follow Up of Plasma Mebendazole Levels and Drug Interactions,” <i>Eur J Clin Pharmacol</i>, 1986, 31:443-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3816925\">[PubMed 3816925]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5865":"<p><b>Title</b> Meperidine / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Meperidine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased analgesic effects of meperidine if phenytoin is initiated/dose increased, or increased effects if phenytoin is discontinued/dose decreased. Phenytoin may also increase the rate of formation of normeperidine, a neuroexcitatory metabolite of meperidine.</p> \n<p><b>Discussion</b> The clearance of meperidine (50 mg intravenous or 100 mg oral) was increased by 27% in healthy volunteers when administered following a 9-day course of phenytoin (300 mg/day).<sup>1</sup> <br><br>The likely mechanism of this interaction is phenytoin induction of meperidine metabolism. This would increase the rate at which normeperidine (the neuroexcitatory metabolite of meperidine) is formed. A study of human liver microsomes demonstrated a role of CYP2B6, 3A4, and 2C19 in catalyzing this metabolism.<sup>2</sup> Phenytoin likely induces all of these enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pond SM and Kretzschmar KM, “Effect of Phenytoin on Meperidine Clearance and Normeperidine Formation,” <i>Clin Pharmacol Ther</i>, 1981, 30:680. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7297025\">[PubMed 7297025]</a></p>\n<p>2. Ramirez J, Innocenti F, Schuetz EG, et al, “CYP2B6, CYP3A4, and CYP2C19 are Responsible for the In Vitro N-Demethylation of Meperidine in Human Liver Microsomes,” <i>Drug Metab Dispos</i>, 2004, 32(9):930-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15319333\">[PubMed 15319333]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5866":"<p><b>Title</b> Methadone / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Methadone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for symptoms of methadone withdrawal upon starting phenytoin. Likewise, monitor for excess sedation upon discontinuation of phenytoin.</p> \n<p><b>Discussion</b> An analysis of 43 patients receiving methadone for treatment of heroin addiction who had withdrawal symptoms found that 10 of these patients had low serum methadone trough (i.e., minimum serum concentration, Cmin) concentrations associated with concurrent use of metabolism-inducing medications, including 4 patients who were receiving concurrent phenytoin therapy.<sup>1</sup> Another 5 patients demonstrated withdrawal symptoms within 3-4 days of initiating phenytoin; methadone serum concentrations were decreased approximately 60%.<sup>2</sup> Another similar case report is also published.<sup>3</sup> The mechanism of this interaction is likely due to the ability of phenytoin to induce the hepatic metabolism of methadone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bell J, Seres V, Bowron P, et al, “The Use of Serum Methadone Levels in Patients Receiving Methadone Maintenance,” <i>Clin Pharmacol Ther</i>, 1988, 43:623-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3378383\">[PubMed 3378383]</a></p>\n<p>2. Tong TG, Pond SM, Kreek MJ, et al, “Phenytoin-Induced Methadone Withdrawal,” <i>Ann Intern Med</i>, 1981, 94:349. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7224382\">[PubMed 7224382]</a></p>\n<p>3. Finelli PF, “Phenytoin and Methadone Tolerance,” <i>N Engl J Med</i>, 1976, 294:227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1244546\">[PubMed 1244546]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5867":"<p><b>Title</b> Fosphenytoin / Methylfolate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methylfolate may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and effectiveness of phenytoin if L-methylfolate is initiated/dose increased. Similarly, monitor for increases in phenytoin concentrations (and possible toxicity) if L-methylfolate is discontinued/dose decreased.</p> \n<p><b>Discussion</b> L-methylfolate (the primary biologically active isomer of folate) prescribing information cautions that high doses of folate may reduce serums levels of anticonvulsants (including phenytoin) and thus increase the seizure frequency in susceptible patients.<sup>1</sup> Serum phenytoin concentrations decreased 30% to 50% in 50 patients within one month of initiating folic acid therapy.<sup>2</sup> In small case series reports and individual case reports, the addition of folic acid at doses of 1mg have been associated with 20-23% reductions in phenytoin concentrations,<sup>3,4</sup> while addition of 5mg doses have been associated with 40-60% reductions in phenytoin concentrations.<sup>5,6</sup> Similar reductions in serum phenytoin concentrations have been reported elsewhere.<sup>7,8,9</sup> Several reports have also described an apparent lack of effectiveness following the addition of folic acid, with reports of breakthrough seizures and/or an increase in seizure episodes.<sup>2,3,6,10,11</sup><br><br>Though the detailed mechanism of this interaction has yet to be fully described, folic acid appears to function as a cofactor in the metabolism of phenytoin, with reports that higher folic acid concentration increase the affinity (i.e., decreased Km) of metabolizing enzymes for phenytoin.<sup>3,4,10,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Deplin (L-methylfolate). Covington, LA: PAMLAB, L.L.C., 2006.</p>\n<p>2. Baylis EM, Crowley JM, Preece JM, et al, “Influence of Folic Acid on Blood-Phenytoin Levels,” <i>Lancet</i>, 1971 i:62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4099219\">[PubMed 4099219]</a></p>\n<p>3. Berg MJ, Fisher LJ, Rivey MP, et al, “Phenytoin and Folic Acid Interaction: A Preliminary Report,” <i>Ther Drug Monit</i>, 1983, 5:389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659012\">[PubMed 6659012]</a></p>\n<p>4. Berg MJ, Ebert BE, Rivey MP, et al, “Utilization of Km for Phenytoin Dosage After Folate Addition to Patient Regimen,” <i>Ther Drug Monit</i>, 1987, 9:304-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3672574\">[PubMed 3672574]</a></p>\n<p>5. Inoue F, Kolabinski I, “Possible Interaction Between Phenytoin Therapy and Folate Supplement: Two Case Reports,” <i>Can J Hosp Pharm</i>, 1986, 39:16-8.</p>\n<p>6. Steinweg DL, Bentley ML, “Seizures Following Reduction in Phenytoin Level After Orally Administered Folic Acid,” <i>Neurology</i>, 2005, 64(11):1982. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955964\">[PubMed 15955964]</a></p>\n<p>7. Glazko AJ, “Antiepileptic Drugs: Biotransformation, Metabolism, and Serum Half-Life,” <i>Epilepsia</i>, 1975, 16:367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=238831\">[PubMed 238831]</a></p>\n<p>8. Jensen ON and Olesen OV, “Subnormal Serum Folate Due to Anticonvulsive Therapy. A Double-Blind Study of the Effect of Folic Acid Treatment in Patients With Drug-Induced Subnormal Serum Folates,” <i>Arch Neurol</i>, 1970, 22:181-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4902774\">[PubMed 4902774]</a></p>\n<p>9. Furlanut M, Benetello P, Avogaro A, et al, “Effects of Folic Acid on Phenytoin Kinetics in Healthy Subjects,” <i>Clin Pharmacol Ther</i>, 1978, 24:294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=688723\">[PubMed 688723]</a></p>\n<p>10. Berg MJ, Rivey MP, Vern BA, et al, “Phenytoin and Folic Acid: Individualized Drug-Drug Interaction,” <i>Ther Drug Monit</i>, 1983, 5:395-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6659013\">[PubMed 6659013]</a></p>\n<p>11. Seligmann H, Potasman I, Weller B, et al, “Phenytoin-Folic Acid Interaction: A Lesson to be Learned,” <i>Clin Neuropharmacol</i>, 1999, 22(5):268-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10516876\">[PubMed 10516876]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5868":"<p><b>Title</b> Fosphenytoin / Methylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methylphenidate may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Prescribing information for methylphenidate states that human pharmacologic studies have been conducted showing that methylphenidate may inhibit the metabolism of anticonvulsants including phenytoin.<sup>1</sup> Cases of phenytoin intoxication following methylphenidate initiation have been reported.<sup>2,3</sup> However, a number of other case reports have been published where this effect was not detected.<sup>4,5</sup><br><br>The mechanism of this potential interaction is unclear, as are the frequency of occurrence and potential clinical significance.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ritalin (methylphenidate). East Hanover, New Jersey: Novartis Pharmaceuticals Corporation, April 2007.</p>\n<p>2. Garrettson KJ, Perel JM, and Dayton PG, “Methylphenidate Interaction With Both Anticonvulsants and Ethyl Biscoumacetate,” <i>JAMA</i>, 1969, 207:2053-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5818377\">[PubMed 5818377]</a></p>\n<p>3. Ghofrani M, “Possible Phenytoin-Methylphenidate Interaction,” <i>Dev Med Child Neurol</i>, 1988, 30(2):267-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3133263\">[PubMed 3133263]</a></p>\n<p>4. Mirkin BL and Wright F, “ Drug Interactions: Effects of Methylphenidate on the Disposition of Diphenylhydantoin in Man,” <i>Neurology</i>, 1971, 21:1123-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5166217\">[PubMed 5166217]</a></p>\n<p>5. Kupferberg HJ, Jeffery W, and Hunninghake DB, “Effect of Methylphenidate on Plasma Anticonvulsant Levels,” <i>Clin Pharmacol Ther</i>, 1972, 13:201-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4552820\">[PubMed 4552820]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5870":"<p><b>Title</b> MetroNIDAZOLE (Systemic) / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for phenytoin toxicity and elevated phenytoin serum concentrations when metronidazole is initiated. Also, monitor for decreased efficacy and/or treatment failure if metronidazole is used in a patient on long-term fosphenytoin therapy.</p> \n<p><b>Discussion</b> In one pharmacokinetic study conducted in 7 healthy volunteers, the AUC of phenytoin (300 mg single intravenous dose) increased 23% and the phenytoin half-life was prolonged 43% when administered after a 4 day course of metronidazole (250 mg orally three times daily).<sup>1</sup> Conversely, another study conducted in 5 healthy volunteers reported that metronidazole (400 mg twice daily for 6 days) had no significant impact on the pharmacokinetics of phenytoin (300 mg oral single dose).<sup>2</sup><br><br>Metronidazole prescribing information cautions that metronidazole may decrease phenytoin clearance and lead to increased serum phenytoin concentrations.<sup>3</sup> Despite a lack of published reports, metronidazole prescribing information also warns that phenytoin may decrease metronidazole concentrations.<sup>3</sup><br><br>Although the mechanisms of these interactions are uncertain, metronidazole may inhibit one or more of the enzymes responsible for phenytoin metabolism and phenytoin may induce the enzyme(s) responsible for metronidazole metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Blyden GT, Scavone JM, Greenblatt DJ. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. <i>J Clin Pharmacol</i>. 1988;28(3):240-245. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360972\">[PubMed 3360972]</a></p>\n<p>2. Jensen JC, Gugler R. Interaction between metronidazole and drugs eliminated by oxidative metabolism. <i>Clin Pharmacol Ther</i>. 1985;37(4):407-410. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3979002\">[PubMed 3979002]</a></p>\n<p>3. <i>Flagyl</i> (metronidazole) [prescribing information]. New York, NY: Pfizer Inc; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5871":"<p><b>Title</b> MetyraPONE / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of MetyraPONE. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The results of the metyrapone test (using standard dosing) will be unreliable in patients receiving phenytoin. Doubling the dosage of metyrapone (750 mg every 2 hours) has been shown to provide near-normal results.</p> \n<p><b>Discussion</b> Serum metyrapone concentrations (750 mg oral) in 3 phenytoin-treated patients were only 14% of the concentrations achieved in 5 normal subjects.<sup>1</sup> The corticosteroid response was similarly reduced. Another report confirms this interaction.<sup>2</sup> Under such circumstances, the results of the test are unreliable. The initial report demonstrated that doubling the dosage (by administering 750 mg every 2 hours instead of every 4 hours) may give results similar to patients not receiving phenytoin.<sup>1</sup> The likely mechanism of this interaction is related to the ability of phenytoin to induce the metabolism of metyrapone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Meikle AW, Jubiz W, Matsukura S, et al, “Effect of Diphenylhydantoin on the Metabolism of Metyrapone and Release of ACTH in Man,” <i>J Clin Endoncrinol Metab</i>, 1969, 29:1553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4310497\">[PubMed 4310497]</a></p>\n<p>2. Werk EE, Thrasher K, Choi Y, et al, “Failure of Metyrapone to Inhibit 11-Hydroxylation of 11-Deoxycortisol During Drug Therapy,” <i>J Clin Endocrinol</i>, 1967, 27:1358. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4292251\">[PubMed 4292251]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5872":"<p><b>Title</b> Mexiletine / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Mexiletine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of mexiletine if phenytoin is initiated/dose increased, or increased effects if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The mean AUC and half-life of mexiletine (single 400 mg dose) were decreased by 55% and 51%, respectively, in 6 healthy volunteers when administered following seven days of phenytoin (300 mg/daily).<sup>1</sup> The magnitude of this pharmacokinetic effect was judged to be likely to result in clinically important changes in mexiletine response.<br><br>The mechanism of this interaction is uncertain, but given the ability of phenytoin to induce several drug metabolizing enzymes and the fact that mexiletine is extensively metabolized (via CYP2D6 and CYP1A2),<sup>2</sup> phenytoin-mediated induction of mexiletine metabolism is a likely mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Begg EJ, Chinwah PM, Webb C, et al, “Enhanced Metabolism of Mexiletine After Phenytoin Administration,” <i>Br J Clin Pharmacol</i>, 1982, 14:219-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7104173\">[PubMed 7104173]</a></p>\n<p>2. Prescribing information. Mexitil (mexiletine). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 05/30/03.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5874":"<p><b>Title</b> Primidone / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Though often used advantageously, monitor for increased serum concentrations of phenobarbital (a metabolite of primidone) during concomitant administration of phenytoin and primidone.</p> \n<p><b>Discussion</b> The serum phenobarbital:primidone ratio is significantly higher in patients receiving primidone plus phenytoin, than in patients receiving only primidone.<sup>1,2,3,4</sup> Primidone is partially metabolized to phenobarbital. Phenytoin apparently induces this conversion pathway. Phenytoin might also compete for sites of phenobarbital metabolism, thus reducing the elimination of the converted product. Though often used advantageously, this combination has resulted in phenobarbital toxicity.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fincham RW, Schottelius DD, and Sahs AL, “The Influence of Diphenylhydantoin on Primidone Metabolism,” <i>Arch Neurol</i>, 1974, 30:259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4812960\">[PubMed 4812960]</a></p>\n<p>2. Schmidt D, “The Effect of Phenytoin and Ethosuximide on Primidone Metabolism in Patients With Epilepsy,” <i>J Neurol</i>, 1975, 209:115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=51048\">[PubMed 51048]</a></p>\n<p>3. Reynolds EJ, Fenton G, Fenwick P, et al, “Interaction of Phenytoin and Primidone,” <i>Br Med J</i>, 1975, 2:594. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1131627\">[PubMed 1131627]</a></p>\n<p>4. Gallagher BB, Baumel IP, Mattson RH, et al, “Primidone, Diphenylhydantoin and Phenobarbital. Aspects of Acute and Chronic Toxicity,” <i>Neurology</i>, 1973, 23:145-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4734509\">[PubMed 4734509]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5875":"<p><b>Title</b> Progestins (Contraceptive) / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. If phenytoin must be used in a patient desiring effective birth control, hormonal contraceptives may not provide adequate protection against conception. Patients must be instructed to use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of hormonal contraceptives, might not be present in spite of the occurrence of an interaction. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Case reports describe women on oral contraceptives who became pregnant during concomitant therapy with phenytoin.<sup>2,3</sup> Contraceptive failure has also been reported when phenytoin was combined with levonorgestrel subdermal capsules.<sup>4,5</sup> The mechanism of this interaction is unknown, but might be a pharmacokinetic effect related to phenytoin-enhanced metabolism of estrogens and/or progestins. Whether the use of lower dose products carries greater risk of therapeutic failure than higher dose products is unclear. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. Kenyon IE, “Unplanned Pregnancy in an Epileptic,” <i>Br Med J</i>, 1972, 1:686. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5015305\">[PubMed 5015305]</a></p>\n<p>3. Janz D and Schmidt D, “Antiepileptic Drugs and Failure of Oral Contraceptives,” <i>Lancet</i>, 1974, i:1113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4135275\">[PubMed 4135275]</a></p>\n<p>4. Odlind V and Olsson SE, “Enhanced Metabolism of Levonorgestrel During Phenytoin Treatment in a Woman With <i>Norplant</i> Implants,” <i>Contraception</i>, 1986, 33:257-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3087695\">[PubMed 3087695]</a></p>\n<p>5. Haukkamaa M, “Contraception by <i>Norplant</i> Subdermal Capsules is Not Reliable in Epileptic Patients on Anticonvulsant Treatment,” <i>Contraception</i>, 1986, 33:559-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3095023\">[PubMed 3095023]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5877":"<p><b>Title</b> Fosphenytoin / Pyridoxine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction has only been suggested at high pyridoxine doses (80-200 mg/day).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pyridoxine may increase the metabolism of Fosphenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily) <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/effects of phenytoin in patients receiving concomitant high-dose pyridoxine (eg, 80-200 mg/day). Typical multiple vitamin preparations are not likely to cause problems.</p> \n<p><b>Discussion</b> Serum phenytoin concentrations were approximately halved in patients (also receiving chronic phenobarbital therapy) following 2-4 weeks of concomitant therapy with pyridoxine (80-200 mg/day).<sup>1</sup> The mechanism of this apparent interaction is unknown. The authors of the report suggest that pyridoxine might increase hepatic enzyme activity, and thus increase phenytoin metabolism. The ability of pyridoxine doses found in typical multiple vitamin preparations to produce these same effects is unknown, but presumed doubtful.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hansson O and Sillanpaa M, “Pyridoxine and Serum Concentration of Phenytoin and Phenobarbitone,” <i>Lancet</i>, 1976, i:256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=55569\">[PubMed 55569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5879":"<p><b>Title</b> QuiNIDine / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may enhance the QTc-prolonging effect of QuiNIDine. Fosphenytoin may decrease the serum concentration of QuiNIDine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to combined use of quinidine and fosphenytoin when possible. Monitor patients receiving this combination closely for signs and symptoms of excessive QTc interval prolongation and arrhythmia, as well as for decreased serum concentrations/therapeutic effects of quinidine.</p> \n<p><b>Discussion</b> The AUC (a measure of drug exposure) of quinidine (300 mg single dose) was decreased by approximately 60% in 4 healthy subjects when administered following a 2-week course of phenobarbital or phenytoin.<sup>1</sup> Serum half-life of quinidine in this study, and others, has been reported to be at least halved by concurrent use of phenobarbital, phenytoin, or primidone (partially metabolized to phenobarbital).<sup>1,2,3,4</sup> <br><br>The presumed mechanism of this interaction is phenytoin induction of quinidine metabolism, likely mediated primarily by CYP3A4 but also possibly involving other enzymes such as CYP2C9.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Data JL, Wilkinson GR, and Nies AS, “Interaction of Quinidine With Anticonvulsant Drugs,” <i>N Engl J Med</i>, 1976, 294:699-702. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1250281\">[PubMed 1250281]</a></p>\n<p>2. Kroboth FJ, Kroboth PD, and Logan T, “Phenytoin-Theophylline-Quinidine Interaction,” <i>N Engl J Med</i>, 1983, 308:724-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6828116\">[PubMed 6828116]</a></p>\n<p>3. Rodgers GC and Blackman MS, “Quinidine Interaction With Anticonvulsants,” <i>Drug Intell Clin Pharm</i>, 1983, 17:819-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6641505\">[PubMed 6641505]</a></p>\n<p>4. Russo ME, Russo J, and Smith RA, “The Effect of Phenytoin on Quinidine Pharmacokinetics,” <i>Drug Intell Clin Pharm</i>, 1982, 16:480.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5880":"<p><b>Title</b> QuiNINE / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of QuiNINE. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Carefully consider the need for this combination due to the risk for impaired quinine effectiveness. Monitor specifically for quinine effectiveness closely, watching for evidence of impaired effectiveness.</p> \n<p><b>Discussion</b> According to quinine prescribing information, phenytoin is expected to decrease quinine serum concentrations, potentially interfering with its clinical effectiveness.<sup>1</sup> Though quinine prescribing information recommends avoiding concurrent use with rifampin, another potent enzyme inducer, such a strong warning/recommendation is not included for phenytoin. Quinine is a substrate for P-glycoprotein, CYP3A4, and other cytochrome P450 enzymes, and it is likely that phenytoin-mediated induction of such transporters and enzymes is largely responsible for this suspected interaction.<sup>1</sup><br><br>The average phenytoin AUC and maximum serum concentration (Cmax) were increased by only 4% each, when single doses of phenytoin (200 mg) and quinine sulfate (600 mg) were coadministered to a group of healthy volunteers (n=8).<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Qualaquin (quinidine). Philadelphia, PA: AR Scientific, Inc., 4/2011.</p>\n<p>2. Amabeoku GJ, Chikuni O, Akino C, et al, “Pharmacokinetic Interaction of Single Doses of Quinine and Carbamazepine, Phenobarbitone and Phenytoin in Healthy Volunteers,” <i>East Afr Med J</i>, 1993, 70(2):90-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8513749\">[PubMed 8513749]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5882":"<p><b>Title</b> Ritonavir / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Dose adjustments of phenytoin may be necessary when using these agents in combination. Increased monitoring of therapeutic response to both agents together with close monitoring of phenytoin concentrations is recommended, particularly with any dose adjustments.</p> \n<p><b>Discussion</b> Studies regarding the interaction between ritonavir and phenytoin have generally reported lower phenytoin concentrations with the combination, though these studies have become complicated by the widespread use of ritonavir in combination with other protease inhibitors, making it difficult to make generalizations regarding the effects of ritonavir vs. other specific agents.<br><br>Concurrent lopinavir/ritonavir (400mg/100mg twice daily) and phenytoin (300mg daily) for 11 days (n=24) was associated with a 30% lower lopinavir AUC, a 35% lower ritonavir AUC, and a 23% lower phenytoin AUC.<sup>1</sup> Minimum and maximum concentrations of all three agents were also substantially (20-50%) lower during combined therapy. According to fosamprenavir prescribing information, amprenavir AUC and minimum concentration (Cmin) were both increased by approximately 20% with combined phenytoin (300mg daily x 10 days) and fosamprenavir/ritonavir (700mg/100mg twice daily x 10 days) in a study of 13 individuals.<sup>2</sup> Amprenavir maximum concentration (Cmax) was not significantly altered with the combination; data regarding the impact on ritonavir concentrations were not reported. Similar to the findings with the phenytoin-lopinavir/ritonavir combination, phenytoin AUC, Cmax, and Cmin were all approximately 20-30% lower with the phenytoin-fosamprenavir/ritonavir combination.<sup>2</sup><br><br>Two published case reports have reported disparate findings regarding a ritonavir-phenytoin interaction. In one report, a change in antiretroviral therapy from stavudine (30mg twice/day), lamivudine (150mg twice/day), and indinavir (800mg three times/day) to ritonavir (300mg twice daily), saquinavir (400mg twice daily), and nevirapine (200mg daily) was associated with a 33% decrease in phenytoin concentrations.<sup>3</sup> Another report describes no evidence of an interaction following a change from estavudine, lamivudine, and indinavir to lamivudine, didanosine, ritonavir (600mg twice/day), and saquinavir.<sup>4</sup><br><br>The mechanism(s) responsible for the mixed effects of phenytoin on ritonavir and other protease inhibitors is/are unclear. The ability of phenytoin to induce various drug metabolizing enzymes is well-recognized, but the manner in which phenytoin increased amprenavir concentrations is unknown. Ritonavir appears to have both enzyme inhibiting and inducing effects, in addition to possible inducing effects on the p-glycoprotein drug transporter. Induction of phenytoin metabolism and/or protein binding displacement are possible mechanisms for the observed reductions in phenytoin concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lim ML, Min SS, Eron JJ, et al, “Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction through Cytochrome P-450 Induction,” <i>J Acquir Immune Defic Syndr</i>, 2004, 36:1034-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15247556\">[PubMed 15247556]</a></p>\n<p>2. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, October 2007.</p>\n<p>3. Mateu-de Antonio J, Grau S, Gimeno-Bayon JL, et al, “Ritonavir-Induced Carbamazepine Toxicity,” <i>Ann Pharmacother</i>, 2001, 35:125-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11197575\">[PubMed 11197575]</a></p>\n<p>4. Berbel Garcia A, Latorre Ibarra A, Porta Etessam J, et al, “Protease Inhibitor-Induced Carbamazepine Toxicity,” <i>Clin Neuropharmacol</i>, 2000, 23:216-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11020127\">[PubMed 11020127]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5883":"<p><b>Title</b> Rufinamide / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased rufinamide levels/effects with phenytoin initiation. Monitor for increased rufinamide levels/effects with phenytoin discontinuation. Conversely, monitor for increased phenytoin levels/effects with rufinamide initiation/dose increases or decreased phenytoin levels/effects with rufinamide discontinuation/dose decreases. Effects may be more pronounced in pediatric patients.</p> \n<p><b>Discussion</b> According to rufinamide prescribing information, concomitant use of rufinamide with phenytoin resulted in decreased rufinamide serum levels (25-46%, independent of phenytoin dose or concentration) and increased phenytoin serum levels (7-21%, dependent on rufinamide concentration).<sup>1</sup> <br><br>Rufinamide is metabolized by carboxylesterases and does not undergo any appreciable CYP-related metabolism. Phenytoin is a substrate for CYP3A4, 2C9, and 2C19 isoenzymes. Both agents induce CYP3A4 (phenytoin strongly; rufinamide weakly). The precise mechanism behind this apparent interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Banzel (rufinamide). Woodcliff Lake, NJ: Novartis Pharma AG, November, 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5884":"<p><b>Title</b> Sertraline / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Sertraline. Sertraline may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced clinical response to sertraline if phenytoin is initiated/dose increased, or increased response/toxicity if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> A review of therapeutic drug monitoring data indicated that dose-corrected sertraline serum concentrations in patients receiving phenytoin or carbamazepine were approximately 32% of those seen in patients not receiving phenytoin or carbamazepine.<sup>1</sup> <br><br>Additionally, two case reports describe patients whose serum phenytoin concentrations increased (by 22% and 450%) following initiation of sertraline.<sup>1</sup> However, a clinical study demonstrated no significant change in phenytoin (100 mg orally three times daily) pharmacokinetic parameters in healthy volunteers given sertraline (200 mg daily for 10 days, following a 7 day dose escalation).<sup>2</sup> <br><br>The likely primary mechanism of interaction between these agents is phenytoin induction of non-CYP2D6 sertraline metabolic pathways (e.g., CYP2B6, 2C9, 2C19, and 3A4). Sertraline may inhibit CYP2C19 and/or 2C9 mediated phenytoin metabolism as well, but effects appear to be minor in most cases.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pihlsgard M and Eliasson E, “Significant Reduction of Sertraline Plasma Levels by Carbamazepine and Phenytoin,” <i>Eur J Clin Pharmacol</i>, 2002, 57(12):915-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936714\">[PubMed 11936714]</a></p>\n<p>2. Haselberger MB, Freedman LS, and Tolbert S, “Elevated Serum Phenytoin Concentrations Associated With Coadministration of Sertraline,” <i>J Clin Psychopharmacol</i>, 1997, 17(2):107-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10950473\">[PubMed 10950473]</a></p>\n<p>3. Rapeport WG, Muirhead DC, Williams SA, et al, “Absence of Effect of Sertraline on the Pharmacokinetics and Pharmacodynamics of Phenytoin,” <i>J Clin Psychiatry</i>, 1996, 57(Suppl 1):24-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8617708\">[PubMed 8617708]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5887":"<p><b>Title</b> Tacrolimus (Systemic) / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased tacrolimus concentrations when fosphenytoin is initiated/dose increased and increased tacrolimus concentrations/toxicity if fosphenytoin is discontinued/dose decreased. Tacrolimus dosage requirements may be greater in patients receiving fosphenytoin. In addition, monitor for increased phenytoin concentrations/effects if tacrolimus is initiated/dose increased.</p> \n<p><b>Discussion</b> One case report describes 2 heart transplant recipients with tacrolimus serum concentration to dose ratios that were significantly lower during concomitant therapy with phenytoin compared with tacrolimus therapy alone.<sup>1</sup> Another report describes a 54-year-old kidney transplant recipient who required tacrolimus 0.25 mg/kg/day while on phenytoin therapy to maintain therapeutic trough levels, but only required tacrolimus 0.16 mg/kg/day to achieve therapeutic concentrations after phenytoin discontinuation.<sup>2</sup> One additional report describes a 19-year-old kidney transplant recipient who had difficulty achieving therapeutic tacrolimus concentrations while on phenytoin therapy.<sup>3</sup> Phenytoin has been used in numerous cases to enhance tacrolimus elimination in cases of tacrolimus toxicity.<sup>4,5,6,7,8</sup> In addition to high tacrolimus dose requirements while on phenytoin therapy, one case report describes a kidney transplant recipient who experienced elevated phenytoin levels after his cyclosporine was changed to tacrolimus.<sup>9</sup> <br><br>Tacrolimus prescribing information states that phenytoin may decrease tacrolimus concentrations. Increased monitoring of tacrolimus concentrations and appropriate dose increases as needed are recommended.<sup>10</sup> Because concomitant administration of phenytoin and tacrolimus may also increase phenytoin concentrations, increased monitoring of phenytoin concentrations is also recommended.<sup>10</sup><br><br>The mechanism by which phenytoin decreases tacrolimus concentrations is likely due to induction of CYP3A4, an enzyme responsible for tacrolimus metabolism. The mechanism by which tacrolimus may increase phenytoin concentrations is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wada K, Takada M, Ueda T, et al. Drug interactions between tacrolimus and phenytoin in Japanese heart transplant recipients: 2 case reports. <i>Int J Clin Pharmacol Ther</i>. 2007;45(9):524-528. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17907595\">[PubMed 17907595]</a></p>\n<p>2. Moreno M, Latorre A, Manzanares C, et al. Clinical management of tacrolimus drug interactions in renal transplant patients. <i>Transplant Proc</i>. 1999;31(6):2252-2253. [PubMed 10500564 ]</p>\n<p>3. Formea CM, Evans CG, Karlix JL. Altered cytochrome p450 metabolism of calcineurin inhibitors: case report and review of the literature. <i>Pharmacotherapy</i>. 2005;25(7):1021-1029. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16006281\">[PubMed 16006281]</a></p>\n<p>4. Patel SJ, Kuten SA, Musick WL, Gaber AO, Monsour HP, Knight RJ. Combination drug products for HIV - a word of caution for the transplant clinician [published online April 18, 2016. <i>Am J Transplant</i>. Doi: 10.1111/ajt.13826. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27089541\">[PubMed 27089541]</a></p>\n<p>5. El-Asmar J, Gonzalez R, Bookout R, Mishra A, Kharfan-Dabaja MA. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury [published online November 27, 2015]. <i>Hematol Oncol Stem Cell Ther</i>. Doi: 10.1016/j.hemonc.2015.11.001. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26684920\">[PubMed 26684920]</a></p>\n<p>6. Bax K, Tijssen J, Rieder MJ, Filler G. Rapid resolution of tacrolimus intoxication-induced AKI with a corticosteroid and phenytoin. <i>Ann Pharmacother</i>. 2014;48(11):1525-1528. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25104567\">[PubMed 25104567]</a></p>\n<p>7. Jantz AS, Patel SJ, Suki WN, Knight RJ, Bhimaraj A, Gaber AO. Treatment of acute tacrolimus toxicity with phenytoin in solid organ transplant recipients [published online June 13, 2013]. <i>Case Rep Transplant</i>. Doi: 10.1155/2013/375263. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23844312\">[PubMed 23844312]</a></p>\n<p>8. Karasu Z, Gurakar A, Carlson J, et al. Acute tacrolimus overdose and treatment with phenytoin in liver transplant recipients. <i>J Okla State Med Assoc</i>. 2001;94(4):121-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11392178\">[PubMed 11392178]</a></p>\n<p>9. Thompson PA, Mosley CA. Tacrolimus-phenytoin interaction. <i>Ann Pharmacother</i>. 1996;30(5):544. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8740340\">[PubMed 8740340]</a></p>\n<p>10. Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5888":"<p><b>Title</b> Temsirolimus / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully monitor for decreased sirolimus (active metabolite) serum concentrations if phenytoin is initiated/dose increased, and for increased concentrations if phenytoin is discontinued/dose decreased. The manufacturer recommends against coadministration with strong CYP3A4 inducers like phenytoin;<sup>1</sup> however, if concurrent therapy is necessary, an increase in the temsirolimus dose to 50 mg/week should be considered. If discontinuing the strong 3A4 inducer, temsirolimus dose should be decreased to the level used prior to initiation of the inducer.</p> \n<p><b>Discussion</b> Concurrent phenytoin (n=6) or carbamazepine (n=5) were associated with decreased temsirolimus and sirolimus (active metabolite of temsirolimus) concentrations in a study of patients with malignant gliomas or brain metastases who were either receiving an enzyme inducing agent (i.e., phenytoin or carbamazepine) or who were not (i.e., controls, n=14).<sup>2</sup> Among those receiving phenytoin or carbamazepine, the temsirolimus AUC and maximum concentration (Cmax) averaged 15% and 36% lower, respectively, and the sirolimus AUC and Cmax averaged 43% and 67% lower, respectively.<br><br>The mechanism of this interaction is likely phenytoin- and carbamazepine-mediated induction of the CYP3A metabolism of both temsirolimus and sirolimus.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Torisel (temsirolimus). Philadelphia, PA: Wyeth Pharmaceuticals Inc., 5/2007.</p>\n<p>2. Boni J, Leister C, Burns J, et al, “Pharmacokinetic Profile of Temsirolimus with Concomitant Administration of Cytochrome P450-Inducing Medications,” <i>J Clin Pharmacol</i>, 2007, 47:1430-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17913896\">[PubMed 17913896]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5889":"<p><b>Title</b> Teniposide / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Teniposide. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to combined treatment with phenytoin and teniposide due to the potential for decreased teniposide concentrations. If the combination cannot be avoided, monitor teniposide response closely.</p> \n<p><b>Discussion</b> The clearance of teniposide was 2.5-fold higher in 6 children with acute lymphocytic leukemia (ALL) receiving phenytoin or phenobarbital than in matched controls.<sup>1</sup> In a retrospective review of children with ALL treated with teniposide, concomitant treatment with phenytoin or phenobarbital (with or without other enzyme-inducing medications) was associated with worse event-free survival, hematologic relapse, and CNS relapse in patients with B-cell lineage malignancies.<sup>2</sup> Additionally, a review of a subset of patients who had teniposide clearance estimates showed greater clearance in patients receiving phenytoin or phenobarbital.<br><br>The mechanism of this interaction has not been investigated. Phenytoin induction of CYP3A mediated teniposide metabolism likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Baker DK, Relling MV, Pui CH, et al, “Increased Teniposide Clearance With Concomitant Anticonvulsant Therapy,” <i>J Clin Oncol</i>, 1992, 10(2):311-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1732431\">[PubMed 1732431]</a></p>\n<p>2. Relling MV, Pui CH, Sandlund JT, et al, “Adverse Effect of Anticonvulsants on Efficacy of Chemotherapy for Acute Lymphoblastic Leukaemia,” <i>Lancet</i>, 2000, 356(9226):285-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11071183\">[PubMed 11071183]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5890":"<p><b>Title</b> Fosphenytoin / Theophylline Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Seek alternatives to this combination when possible. If these agents are used together, monitor closely for decreased serum concentrations/therapeutic effects of phenytoin or theophylline if the other agent is initiated/dose increased, or increased concentrations/toxic effects if the other agent is discontinued/dose decreased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline*, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The half-life of theophylline (administered as aminophylline 5.6 mg/kg IV over 30 minutes) was decreased by approximately 50% in 10 normal subjects when administered following a 10-day (minimum) course of phenytoin (300-400 mg/day).<sup>1</sup> Other reports demonstrate increased clearance of theophylline in both normal subjects and patients during concomitant phenytoin therapy.<sup>2,3,4</sup> This interaction is likely due to the ability of phenytoin to induce CYP3A4 isoenzymes, and thus increase theophylline metabolism.<br><br>Mean serum phenytoin concentrations increased by 30% in 14 normal subjects following the discontinuation of theophylline dosing.<sup>5</sup> Theophylline and phenytoin had been coadministered for approximately 2 weeks. The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Marquis JF, Carruthers SG, Spense JD, et al, “Phenytoin-Theophylline Interaction,” <i>N Engl J Med</i>, 1982, 307:1189-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7121545\">[PubMed 7121545]</a></p>\n<p>2. Miller M, Cosgriff J, Kwong T, et al, “Influence of Phenytoin on Theophylline Clearance,” <i>Clin Pharmacol Ther</i>, 1984, 35:666-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6713777\">[PubMed 6713777]</a></p>\n<p>3. Sklar SJ and Wagner JC, “Enhanced Theophylline Clearance Secondary to Phenytoin Therapy,” <i>Drug Intell Clin Pharm</i>, 1985, 19:34-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3967572\">[PubMed 3967572]</a></p>\n<p>4. Reed RC and Schwartz HJ, “Phenytoin-Theophylline-Quinidine Interaction,” <i>N Engl J Med</i>, 1983, 308:724-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6828116\">[PubMed 6828116]</a></p>\n<p>5. Taylor JW, Hendeles L, Weinberger M, et al, “The Interaction of Phenytoin and Theophylline,” <i>Drug Intell Clin Pharm</i>, 1980, 14:638.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5891":"<p><b>Title</b> Thyroid Products / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of thyroid products if phenytoin is initiated/dose increased. TSH may be elevated. Other measures of thyroid function (e.g., T<sub>4</sub>,T<sub>3</sub>) may be variably altered. Also note that thyroid concentrations/effects may be increased following phenytoin dose reduction or discontinuation.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n</div> \n<p><b>Discussion</b> A study in which six levothyroxine-stable female patients were administered phenytoin (350 mg/day) demonstrated a complex interaction between phenytoin and levothyroxine.<sup>1</sup> They noted a decrease in the amount of levothyroxine absorbed across the gut wall and an increase in nondeionative metabolism of levothyroxine. Although the fraction of T<sub>4</sub> converted to T<sub>3</sub> increased and the fraction of T<sub>4</sub> converted to rT<sub>3</sub> decreased, there was no change in the absolute amount of T<sub>3</sub> produced.<sup>1</sup> A case report describes a levothyroxine-stable patient who became hypothyroid after initiating phenytoin therapy (300 mg/day).<sup>2</sup> Subsequent dechallenge and rechallenge with phenytoin confirmed its role in the interaction.<br><br>Phenytoin likely increases the cytochrome P450 (CYP)-mediated metabolism of the thyroid product. In addition, phenytoin may displace the thyroid product from its protein binding site, presenting more for CYP metabolism.<sup>3</sup> A study in the rat indicates that while the free fraction of T<sub>4</sub> is elevated in vitro, there is no significant change in vivo, likely due to a phenytoin-related alteration in the protein binding of thyroid hormone.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Faber J, Lumholtz IB, Kirkegaard C, et al, “The Effects of Phenytoin (Diphenylhydantoin) on the Extrathyroidal Turnover of Thyroxine, 3,5,3’-Triiodothyronine, 3,3’,5’-Triiodothyronine, and 3’,5’-Diiodothyronine in Man,” <i>J Clin Endocrinol Metab</i>, 1985, 61(6):1093-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4055984\">[PubMed 4055984]</a></p>\n<p>2. Blackshear JL, Schultz AL, Napier JS, et al, “Thyroxine Replacement Requirements in Hypothyroid Patients Receiving Phenytoin,” Ann Intern Med, 1983, 99:341. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6614682\">[PubMed 6614682]</a></p>\n<p>3. Franklyn JA, Sheppard MC, and Ramsden DB, “Measurement of Free Thyroid Hormones in Patients on Long-Term Phenytoin Therapy,” Eur J Clin Pharmacol, 1984, 26:633-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6468481\">[PubMed 6468481]</a></p>\n<p>4. Goussis OS, Theodoropoulos TJ, “Dilantin and Salicylate Effects on Hepatic Thyroxine Bio-availability and Dialyzable Thyroxine,” <i>Horm Meta Res</i>, 1990, 22(6):342-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2379917\">[PubMed 2379917]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5892":"<p><b>Title</b> Fosphenytoin / Ticlopidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ticlopidine may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for increased serum concentration/systemic effects of phenytoin following ticlopidine initiation/dose increase, and decreased concentration/effects following ticlopidine discontinuation/dose decrease.</p> \n<p><b>Discussion</b> Several published case reports describe 2-3 fold increases in serum phenytoin concentrations occurring within 1-6 weeks of initiating ticlopidine therapy.<sup>1,2,3,4,5</sup> All increases were associated with signs and symptoms consistent with phenytoin toxicity. Reductions in phenytoin dosage proved effective in managing the apparent interactions. Dechallenge and rechallenge with ticlopidine provided additional evidence of an interaction in two cases.<sup>4,5</sup> Additionally, in a clinical study of 6 phenytoin-treated patients, coadministration of ticlopidine (250 mg twice daily) significantly decreased phenytoin clearance (as reflected by an approximate doubling of the estimated Michaelis-Menten constant).<sup>6</sup><br><br>The suspected primary mechanism leading to the above affects is ticlopidine competitive inhibition of enzymes mediating phenytoin metabolism (primarily CYP2C19, possibly 2C9 as well).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Donahue S, Flockhart DA and Abernethy DR, “Ticlopidine Inhibits Phenytoin Clearance,” <i>Clin Pharmacol Ther</i>, 1999, 66(6):563-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10613611\">[PubMed 10613611]</a></p>\n<p>2. Donahue SR, Flockhart DA, Abernethy DR, et al, “Ticlopidine Inhibition of Phenytoin Metabolism Mediated by Potent Inhibition of CYP2C19,” <i>Clin Pharmacol Ther</i>, 1997, 62:572-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9390115\">[PubMed 9390115]</a></p>\n<p>3. Privitera M and Welty TE, “Acute Phenytoin Toxicity Followed by Seizure Breakthrough From a Ticlopidine-Phenytoin Interaction,” <i>Arch Neurol</i>, 1996, 53:1191-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8912496\">[PubMed 8912496]</a></p>\n<p>4. Rindone JP and Bryan G, “Phenytoin Toxicity Associated With Ticlopidine Administration,” <i>Arch Intern Med</i>, 1996, 156:1113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8639000\">[PubMed 8639000]</a></p>\n<p>5. Riva R, Cerullo A, Albani F, et al, “Ticlopidine Impairs Phenytoin Clearance: A Case Report,” <i>Neurology</i>, 1996, 46:1172. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8780118\">[PubMed 8780118]</a></p>\n<p>6. Klaassen SL, “Ticlopidine-Induced Phenytoin Toxicity,” <i>Ann Pharmacother</i>, 1998, 32(12):1295-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9876809\">[PubMed 9876809]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5893":"<p><b>Title</b> Tipranavir / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when combining phenytoin and tipranavir/ritonavir as each may increase metabolism of the other. Monitor plasma concentrations and response to therapy closely; dose adjustments may be necessary.</p> \n<p><b>Discussion</b> Though specific phenytoin-tipranavir/ritonavir data are not available, tipranavir prescribing information urges caution when using the combination due to the risk for a drug interaction.<sup>1</sup> As an example of this potential for such agents to interact with one another, one case report involving phenytoin and ritonavir-boosted lopinavir found that both treatments decreased the concentration of one another (phenytoin AUC decreased 23%, lopinavir AUC decreased 30%).<sup>2</sup><br><br>Another case report describes a possible interaction between phenobarbital and tipranavir/ritonavir in which the patient experienced a seizure associated with a 50% decrease in phenobarbital concentrations.<sup>3</sup> A 50% increase in phenobarbital dose was required to restore phenobarbital concentrations to baseline. This case is of relevance as phenobarbital and phenytoin are both metabolized by CYP2C9 and CYP2C19,<sup>4,5,6</sup> and a study described in the tipranavir prescribing information found that ritonavir-booster tipranavir (500mg tipranavir plus 200mg ritonavir twice daily x 10 days) potently induced activity of the CYP2C19 enzyme and had no net effect on CYP2C9.<sup>1</sup> Whether these effects are due to the tipranavir content, ritonavir content, or both is unclear.<br><br>Like phenobarbital and carbamazepine, phenytoin is considered a potent inducer of several metabolic enzymes and drug transporters. Though little specific data concerning combined phenytoin (or phenobarbital and carbamazepine) and tipranavir are available, caution is urged when combining these agents with tipranavir due to the potential for decreased tipranavir concentrations and effectiveness.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 10/2007.</p>\n<p>2. Lim ML, Min SS, Eron JJ, et al, “Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction through Cytochrome P-450 Induction,” <i>J Acquir Immune Defic Syndr</i>, 2004, 36:1034-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15247556\">[PubMed 15247556]</a></p>\n<p>3. Bonora S, Calcagno A, Fontana S, et al, “Clinically Significant Drug Interaction between Tipranavir-Ritonavir and Phenobarbital in an Hiv-Infected Subject,” <i>Clin Infect Dis</i>, 2007, 45:1654-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18190336\">[PubMed 18190336]</a></p>\n<p>4. Yukawa E,Mamiya K, “Effect of Cyp2c19 Genetic Polymorphism on Pharmacokinetics of Phenytoin and Phenobarbital in Japanese Epileptic Patients Using Non-Linear Mixed Effects Model Approach,” <i>J Clin Pharm Ther</i>, 2006, 31:275-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16789993\">[PubMed 16789993]</a></p>\n<p>5. Giancarlo GM, Venkatakrishnan K, Granda BW, et al, “Relative Contributions of Cyp2c9 and 2c19 to Phenytoin 4-Hydroxylation in Vitro: Inhibition by Sulfaphenazole, Omeprazole, and Ticlopidine,” <i>Eur J Clin Pharmacol</i>, 2001, 57:31-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11372587\">[PubMed 11372587]</a></p>\n<p>6. Hung CC, Lin CJ, Chen CC, et al, “Dosage Recommendation of Phenytoin for Patients with Epilepsy with Different Cyp2c9/Cyp2c19 Polymorphisms,” <i>Ther Drug Monit</i>, 2004, 26:534-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15385837\">[PubMed 15385837]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5894":"<p><b>Title</b> Topiramate / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased topiramate serum concentrations and effects when fosphenytoin is initiated or the dose is increased. Some patients may also experience increased phenytoin levels when topiramate is added to fosphenytoin therapy.</p> \n<p><b>Discussion</b> In a study of 12 patients with epilepsy, topiramate (400 to 800 mg per day) clearance increased 2-fold during treatment with phenytoin.<sup>1</sup>The mean phenytoin AUC was unchanged during treatment with topiramate, but 3 patients showed a 25%, 39%, and 55% increase in phenytoin AUC, respectively.<sup>1</sup> In a pharmacokinetic study described in topiramate prescribing information, concomitant administration of phenytoin caused a 48% decrease in topiramate AUC. Phenytoin AUC was often unchanged, but some patients experienced phenytoin AUC increases up to 25%.<sup>2</sup><br><br>In a prospective observational study of 116 patients with epilepsy taking topiramate, topiramate clearance was 1.5-fold higher in the 73 patients who were also taking enzyme inducing antiepileptic drugs (ie, phenytoin, phenobarbital, carbamazepine) compared with 43 patients who were not taking enzyme inducing antiepileptic drugs.<sup>3</sup> Two retrospective analyses of topiramate treated patients found that the topiramate serum concentration to dose ratio was significantly lower in patients receiving topiramate in combination with phenytoin, compared to patients who received topiramate alone or in combination with lamotrigine or valproic acid.<sup>4,5</sup><br><br>The mechanism by which phenytoin may decrease topiramate concentrations has not been fully evaluated, but phenytoin may induce the phase 2 glucuronidation of topiramate. The weak inhibition of CYP2C19 by topiramate appears to be the primary mechanism for the increase in phenytoin concentrations documented in some patients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sachdeo RC, Sachdeo SK, Levy RH, et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. <i>Epilepsia</i>. 2002;43(7):691-696. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12102670\">[PubMed 12102670]</a></p>\n<p>2. Topamax (topiramate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; December 2014.</p>\n<p>3. Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. <i>Ther Drug Monit</i>. 2002;24(3):332-337. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021622\">[PubMed 12021622]</a></p>\n<p>4. Adin J, Gomez MC, Blanco Y, Herranz JL, Armijo JA. Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. <i>Ther Drug Monit</i>. 2004;26(3):251-257. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15167623\">[PubMed 15167623]</a></p>\n<p>5. May TW, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. <i>Ther Drug Monit</i>.2002;24(3):366-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021627\">[PubMed 12021627]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5895":"<p><b>Title</b> Trimethoprim / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects. Monitor patients receiving this combination closely for both of these possible effects.</p> \n<p><b>Discussion</b> In a clinical study of healthy volunteers, administration of trimethoprim (320 mg/day for 7 days) increased the half-life of phenytoin (single intravenous dose) by 51%.<sup>1</sup> Additionally, two case reports have been published describing development of symptoms of phenytoin toxicity in patients receiving trimethoprim/sulfamethoxazole.<sup>2,3</sup><br><br>The likely primary mechanism of interaction between these agents is trimethoprim inhibition of CYP2C9 mediated phenytoin metabolism. In addition to this, phenytoin may theoretically decrease trimethoprim systemic exposure via induction of its metabolism via CYP3A4 and/or CYP2C9.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hansen JM, Kampmann JP, Siersbaek-Nielsen K, et al, “The Effect of Different Sulfonamides on Phenytoin Metabolism in Man,” <i>Acta Med Scand Suppl</i>, 1979, 624:106. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=284708\">[PubMed 284708]</a></p>\n<p>2. Gillman MA and Sandyk R, “Phenytoin Toxicity and Co-Trimoxazole,” <i>Ann Intern Med</i>, 1985, 102(4):559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3872091\">[PubMed 3872091]</a></p>\n<p>3. Wilcox JB, “Phenytoin Intoxication and Cotrimoxazole,” <i>N Z Med J</i>, 1981, 94(692):235-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6975449\">[PubMed 6975449]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5898":"<p><b>Title</b> Fosphenytoin / Vigabatrin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vigabatrin may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of phenytoin with concurrent vigabatrin.</p> \n<p><b>Discussion</b> Several studies have shown 20% to 30% decreases in serum phenytoin concentrations in patients receiving vigabatrin.<sup>1,2,3,4,5,6</sup> At times, this decrease results in subtherapeutic serum phenytoin concentrations. The mechanism of this interaction appears to be increased phenytoin metabolism via vigabatrin-mediated CYP2C9 induction.<sup>7</sup> Further, one report using both IV and oral phenytoin showed little difference in effect between the two, supporting that vigabatrin does not likely affect phenytoin absorption (at least as its primary effect).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rimmer EM and Richens A, “Double-Blind Study of Gamma-Vinyl GABA in Patients With Refractory Epilepsy,” <i>Lancet</i>, 1984, i:189-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6141335\">[PubMed 6141335]</a></p>\n<p>2. Gatti G, Bartoli A, Marchiselli R, et al, “Vigabatrin-Induced Decrease in Serum Phenytoin Concentration Does Not Involve a Change in Phenytoin Bioavailability,” <i>Br J Clin Pharmacol</i>, 1993, 36:603-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12959280\">[PubMed 12959280]</a></p>\n<p>3. Browne TR, Mattson RH, Penry JK, et al, “A Multicentre Study of Vigabatrin for Drug-Resistant Epilepsy,” <i>Br J Clin Pharmacol</i>, 1989, 95-100S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2667606\">[PubMed 2667606]</a></p>\n<p>4. Rimmer EM and Richens A, “Interaction Between Vigabatrin and Phenytoin,” <i>Br J Clin Pharmacol</i>, 1989, 27:27-33S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2757906\">[PubMed 2757906]</a></p>\n<p>5. Browne TR, Mattson RH, Penry JK, et al, “Vigabatrin for Refractory Complex Partial Seizures; Multicenter Single-Blind Study With Long-Term Follow Up,” <i>Neurology</i>, 1987, 37:184-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3808298\">[PubMed 3808298]</a></p>\n<p>6. Tassinari CA, Michelucci R, Ambrosetto G, et al, “Double-Blind Study of Vigabatrin in the Treatment of Drug-Resistant Epilepsy,” <i>Arch Neurol</i>, 1987, 44:907-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2887152\">[PubMed 2887152]</a></p>\n<p>7. Prescribing information. Sabril (vigabatrin). Deerfield, IL: Lundbeck Inc., August 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5899":"<p><b>Title</b> Zonisamide / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Zonisamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor zonisamide serum concentrations during concomitant therapy with phenytoin. Increased zonisamide doses may be necessary. Monitor for evidence of CNS depression.</p> \n<p><b>Discussion</b> The AUC of zonisamide is significantly decreased during concomitant administration of phenytoin.<sup>1</sup> In contrast, zonisamide does not affect phenytoin pharmacokinetics.<sup>1,2</sup> Phenytoin appears to increase the CYP3A4-mediated metabolism of zonisamide. Additive CNS depressant effects may be evident, too.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shinoda M, Akita M, Hasegawa M, et al, “The Necessity of Adjusting the Dosage of Zonisamide When Coadministered with Other Anti-epileptic Drugs,” <i>Biol Pharm Bull</i>, 1996, 19(8):1090-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8874824\">[PubMed 8874824]</a></p>\n<p>2. Levy RH, Ragueneau-Majlessi I, Garnett WR, et al, “Lack of a Clinically Significant Effect of Zonisamide on Phenytoin Steady-State Pharmacokinetics in Patients with Epilepsy,” <i>J Clin Pharmacol</i>, 2004, 44(11):1230-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15496640\">[PubMed 15496640]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}